Outpatient subcutaneous injection therapy : drug use problems with low-molecular-weight heparins and impact of pharmaceutical care by Mengiardi, Seraina
   
Outpatient Subcutaneous Injection Therapy – 
Drug Use Problems with Low-Molecular-Weight Heparins 
and Impact of Pharmaceutical Care  
 
 
Inauguraldissertation 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
 
Seraina Mengiardi 
aus Ardez und Chur (GR) 
 
 
Basel, 2012  
 
  
 
  
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
 
 
 
Prof. Dr. sc. nat. Kurt E. Hersberger 
Prof. Dr. med. Dr. pharm. Stephan Krähenbühl 
 
 
 
Basel, den 13. Dezember 2011 
 
 
 Prof. Dr. Martin Spiess 
 Dekan 
 
  
 
 
 
 
 
 
 
 
 
 To my family 
Acknowledgements 
 
 6
Acknowledgements 
This work has been carried out at the Pharmaceutical Care Research Group, 
Department of Pharmaceutical Sciences, at the University of Basel under the 
supervision of Prof. Dr. sc. nat. Kurt E. Hersberger and Prof. Dr. med. Dr. pharm. 
Stephan Krähenbühl. 
 
My thanks are offered to all the people who contributed in any way to the completion 
of this thesis.  
 
First of all, I would like to sincerely thank Prof. Dr. sc. nat. Kurt E. Hersberger for his 
boundless support, enthusiasm, and helpfulness throughout this period. I am very 
grateful for all the valuable discussions and ideas, his untiring dedication, and his 
humanity.  
  
I wish to express my gratitude to Prof. Dr. med. Dr. pharm. Stephan Krähenbühl for 
assuming the co-reference of this thesis and for supporting this work. His helpful 
suggestions contributed to the successful completion of this thesis. 
 
My sincere thanks also go to Prof. Dr. med. Dimitrios A. Tsakiris for his essential 
support and help throughout the thesis, for the inspiring discussions, and for his 
kindly assistance.  
 
Many thanks are offered to Dr. phil. II Markus L. Lampert for his support and 
motivation during the thesis, for giving me the opportunity to qualify in Clinical 
Pharmacy („Fähigkeitsausweis FPH in klinischer Pharmazie“), and for offering a 
perspective for the time after the PhD. 
 
My thanks go to Prof. Dr. Christoph R. Meier for accepting the function of 
representative of the Faculty.  
 
Additionally, I would like to thank Prof. Dr. med. Rudolf Bruppacher for his helpful 
inspiration and comments in the framework of the seminar in clinical pharmacy, 
Acknowledgements 
 7
Michael Mittag for his support in analysis and statistics, Paul Lavender for his English 
reviews, and Joëlle Bader for her assistance. 
 
I would like to thank Pfizer AG for their financial support of the studies (Investigator-
Initiated Research Grant).  
 
Many thanks go to all colleagues of the Pharmaceutical Care Research Group, 
especially to Dr. Patrick Eichenberger, Fabienne Böni, Philipp Walter, Markus 
Messerli, Esther Spinatsch, Carole Kaufmann, Dr. Isabelle Arnet, Dr. Vera Bernhardt, 
Corinne Zöbeli, Dr. Jörg Indermitte, Verena Renggli, and Franziska Ankli for the great 
teamwork and pleasant atmosphere in the team. Many thanks also go to my 
colleagues at the Clinical Pharmacy & Epidemiology and Clinical Pharmacology & 
Toxicology units, especially to Dr. Yolanda Brauchli, Dr. Birk Poller, Dr. Dr. Felix 
Hammann, Dr. Sabin Egger, Dr. Alexandra Rätz Bravo, Dr. Michael Bodmer, Dr. 
Oliver Kummer, PD Dr. Manuel Haschke, Prof. Dr. Jürgen Drewe, Dr. Cornelia 
Schneider, Carmen Franz, Patrick Imfeld, Julia Spöndlin, and Saskia Bruderer. 
Thanks to Stefan Winzap for being the heart and soul of the Pharmacenter. 
 
I would like to thank Judith Kaiser and Raphaela von Grünigen for their excellent 
work, in the context of their Master’s theses, in our team. 
 
At this point, I would like to express my gratitude to my parents, to my brother, and to 
my fiancé Marek for their empathy and encouragement. My deepest thanks for 
offering all these opportunities to me, for supporting me wherever life would take me, 
and for being such a good family to me. Grazcha fich! 
 
The time as a PhD student took me in new directions both from professional point of 
view and also a personal one. I’m very grateful for this experience, and for all the 
fortunate coincidences that came my way. 
 
Abbreviations 
 8 
 
Abbreviations 
α Cronbach’s alpha reliability coefficient 
CI confidence interval 
ClinS clinical setting arm 
ClinS-C control group of the clinical setting arm 
ClinS-I intervention group of the clinical setting arm 
DailyS daily life setting arm 
DailyS-C control group of the daily life setting arm 
DailyS-I intervention group of the daily life setting arm 
DOT direct observation technique 
DRP drug-related problems 
DVT deep vein thrombosis 
ECMD electronic compliance monitoring devices 
e-MCM electronic multidrug compliance monitoring 
Fig. figure 
FIP International Pharmaceutical Federation 
GP general practitioner 
GP glycoprotein 
h hour 
HIT heparin-induced thrombocytopenia 
HIV human immunodeficiency virus 
IIRG Investigator-Initiated Research Grant 
i.m. intramuscular 
INR international normalized ratio 
IQR interquartile range 
i.v. intravenous 
l litre 
LMWH low-molecular-weight heparin 
MEMS® Medication Event Monitoring System 
n number 
N Newton 
NHS National Health Service 
Abbreviations 
 9
NMS New Medicine Service  
NSAR non-steroidal anti-rheumatic 
OTC over the counter 
PC pharmaceutical care 
PE pulmonary embolism 
r Spearman’s correlation coefficient 
RCT randomized controlled trial 
s.c. subcutaneous 
SMS text message 
SOP standard operating procedure 
TDM therapeutic drug monitoring 
UFH unfractionated heparin  
USB Universal Serial Bus 
VAS visual analog scale 
VKA vitamin K antagonists 
VTE venous thromboembolism 
WHO World Health Organization 
Table of contents 
 10
Table of contents 
Acknowledgements.................................................................................................. 6 
Abbreviations............................................................................................................ 8 
Table of contents.................................................................................................... 10 
Summary ................................................................................................................. 13 
1 General introduction ....................................................................................... 18 
1.1 Anticoagulants............................................................................................ 18 
1.1.1 Thrombosis and embolism .................................................................. 18 
1.1.2 Antithrombotic drugs ........................................................................... 19 
1.2 Subcutaneous injection therapy ................................................................. 24 
1.2.1 Pre-filled syringes and related systems............................................... 24 
1.2.2 Low-molecular-weight heparin devices ............................................... 25 
1.2.3 Subcutaneous injection technique....................................................... 28 
1.3 Handling difficulties and drug use problems with medication ..................... 29 
1.4 Pharmaceutical Care.................................................................................. 30 
1.5 Compliance ................................................................................................ 33 
1.6 Rationale and aims of the thesis ................................................................ 38 
2 Handling difficulties and drug use problems with pre-filled syringes........ 41 
2.1 Project A: Pitfalls in patient self-management of subcutaneous drug 
application: removal of rubber protection caps from ready-to-use syringes .......... 42 
2.2 Project B: Drug use problems with self-injected low-molecular-weight 
heparins in primary care........................................................................................ 47 
 
Table of contents 
 11
3 Outpatient low-molecular-weight heparin therapy ....................................... 74 
Project C: Self-management of outpatient low-molecular-weight heparin therapy: 
impact of pharmaceutical care .............................................................................. 75 
4 General discussion and conclusions .......................................................... 103 
5 References ..................................................................................................... 111 
6 Appendix ........................................................................................................ 126 
Curriculum vitae ................................................................................................... 158 
  
Summary 
 13
Summary 
Arterial and venous thromboses are important diseases associated with significant 
morbidity, mortality, and costs. To date, the orally taken vitamin K antagonists are, 
together with the parenterally administered heparins, still the most frequently used 
anticoagulants. There is a need for novel agents that are characterized by similar 
effectiveness, but lack the limitations seen in the well-established antithrombotic 
drugs.  
Pre-filled syringes constitute one of the fastest growing markets in the drug delivery 
sectors, driven by a marked rise in the success of biopharmaceuticals (e.g., 
heparins). In Switzerland, all low-molecular-weight heparins (LMWH) and 
fondaparinux are administered subcutaneously (s.c.) with pre-filled syringes. Besides 
the selection of the most appropriate injection site for each individual, a proper 
injection technique contributes to a safe and positive outcome. Self-injections in an 
outpatient setting are of increasing importance as they strengthen the patient’s 
responsibility for his/her own disease management, grant greater independence, and 
reduce costs by minimizing visits to the general practitioner, hospital, or nursing 
service.  
Reasons for handling difficulties and drug use problems are diverse and may lead to 
dosing errors or non-compliance. They are either related to patient’s impairment or to 
the medication, its packaging, or its device. Pharmaceutical care concentrates on the 
process of ‘drug use’, characterized by its dynamic and continuous nature. It is based 
on an active relationship with the patient, and aims to develop an individualized, 
patient-centered, and goal-oriented treatment plan to optimize safety and 
effectiveness. The process consists of the assessment of drug-related problems 
(DRP), the implementation of a care plan to solve and prevent DRP, patient action, 
and a periodic outcome evaluation. 
Poor compliance shows a high prevalence of about 50%, leading to poor clinical 
outcomes, mortality, and increased health-care costs. Ten types of non-compliance 
are known, which can be categorized as intentional or unintentional and which are 
influenced by the patient’s beliefs and concerns about the treatment. Potential 
barriers include patient-related factors, social and economic factors, health-care 
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system-related factors, condition-related factors, and therapy-related factors. 
Strategies to improve compliance comprise multifaceted, patient-tailored 
interventions. Compliance is assessed by indirect or direct methods. To date, there is 
no established gold standard to measure compliance behaviour. A multi-method 
approach combining self-reports and objective measures is the current state-of-the-
art. 
 
It was the goal of this thesis to identify drug use problems and handling difficulties 
with pre-filled injection systems and to evaluate the impact of pharmaceutical care on 
outpatient s.c. injection therapies. The thesis consists of three projects:  
 
The objective of project A was to investigate one single handling difficulty that, to our 
knowledge, had not been reported in the literature so far. We aimed at comparing 
subjectively and objectively measured pull-off forces required to remove the needle 
shield of commercial LMWH pre-filled syringes (Clexane old and new devices, 
Fragmin, Fraxiparine, Sandoparin, Arixtra).  
Three methodological approaches were used:  
 self-assessment by a study population using a visual analog scale (VAS) 
 simultaneous observer’s assessment using a 3-point scale (‘no effort needed’, 
‘effort needed’, or ‘can not remove the needle shield’) 
 mechanical pull-off tests (measurements in Newtons) 
The study population included 68 persons with a median age of 29 years. The 
removal of the needle shield was not possible in 5 of 204 cases, involving four 
subjects and two brands. Significant differences between the VAS scores were 
detected. The observer’s results confirmed these findings, as did the mechanical 
cap-pull-off tests. Measurements of the mechanical pull-off forces showed a large 
range of median forces (13.6─29.9 Newtons) were needed to remove the needle 
shields, with the highest forces needed for Fraxiparine and the old Clexane device. 
Significant differences between different lots of the same brand were detected only 
with Fraxiparine.  
In conclusion, important differences between brands were observed. Health-care 
professionals should be aware of these possibly crucial handling difficulties and their 
consequences for successful therapy and compliance.  
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A literature search failed to find any studies on application problems pertaining to the 
self-injection of LMWH in a heterogeneous outpatient population under daily-life 
conditions. In project B, we therefore designed a prospective cross-sectional study 
using pharmacy customers with the aim of recording drug use problems, patient 
satisfaction, compliance, problems arising from the injection site (abdomen vs. thigh), 
and residual drug volumes in used pre-filled syringes.  
Data were collected during recruitment and by means of structured questionnaire-
based telephone interviews that were carried out at the beginning and the end of the 
LMWH treatment.  
The median age of the 213 patients enrolled in the study was 54 years; of these, 
15.5% had their injections administered by a third person. The rate of self-reported 
non-compliance was 17.1%. At least one relevant problem was recorded in 85.0% of 
the cases. At the end of the treatment, 38.9% of the patients stated self-
administration of the injections required some effort. The preferred injection site was 
the thigh (68.5%). An overall mean residual drug volume ≥10.0% was detected for 
3.9% of the patients. If residual drug was present, a median of 11.2% (IQR 
8.6─17.6%) of the total drug volume had not been injected. Patients injecting into the 
thigh showed a higher risk of leaving residual medication (odds ratio 2.16, 95% 
confidence interval 1.04─4.51).  
 
The effectiveness of community-pharmacy-based interventions in preventing 
problems that arise during s.c. self-injections of LMWH was unknown. Therefore, in 
project C, we aimed to:  
 develop a standard operating procedure (SOP) for the first instruction in the 
s.c. injection technique given by a community pharmacist and the subsequent 
pharmaceutical care provided during outpatient therapy 
 compare intensive pharmaceutical care vs. standard care in both a clinical 
setting under study conditions and a daily life setting  
We hypothesized that:  
 intensive pharmaceutical care for outpatients self-injecting LMWH results in 
improved compliance, safety, and satisfaction, as well as in fewer 
complications 
 the interventions used are feasible in the everyday routine of community 
pharmacies 
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 the results achieved in the clinical and daily life settings are comparable  
In the clinical setting (randomized controlled trial), patients were recruited 
sequentially in hospital wards; in the daily life setting (controlled trial), recruitment 
took place in community pharmacies. Interventions were offered according to patient 
needs. Data were collected by means of a monitored self-injection at home and 
structured questionnaire-based telephone interviews at the beginning and the end of 
the LMWH treatment.  
The median age of the 139 patients was 54 years. Interventions resulted in improved 
s.c. injection technique (p<0.01) and knowledge (p=0.03). Oral instructions were 
pivotal for improving patients’ injection technique. We found no significant differences  
between the intervention groups of the clinical and daily life settings concerning 
quality of the s.c. injection technique, knowledge, compliance, and self-assessed 
assistance quality. Patients’ compliance rate was high (95.8%) as were their baseline 
skills, with the lowest score being 0.86 on a range of −2.00 to +2.00 making further 
improvement difficult.  
 
In conclusion this thesis showed that: 
 
 The pull-off forces required to remove the needle shields of LMWH pre-filled 
syringes correspond roughly to the force needed to hold a narrow-neck plastic 
flask containing 1─3 l of water by pinching the neck between a finger and 
thumb. This seemed to be a so far unnoticed drug use problem. 
 
 Drug use problems with outpatient s.c. injection therapies are very prevalent, 
diverse, and complex. They may be associated with the injection itself or with 
the handling of the injection-device. No associations with any factors studied 
were observed with non-compliance, the injection site (beside residual drug), 
and discomfort or effort required (beside prior injection use).  
 
 The overall mean residual drug volume was negligible, but the total injection 
volume seemed to have an influence. If residual drug was present, however, it 
tended to be of pharmacological relevance. Patients injecting into the thigh 
showed a higher risk of leaving medication.  
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 From a patient’s point of view, injections require some effort. Patients have 
concerns with pre-filled syringes, but are aware of their need. Further research 
should investigate whether compliance is not only disease- and time-
dependent, but also device-dependent. We assume that intentional non-
compliance might be lower with s.c. self-injections than with oral 
administration. 
 
 The provided SOP for pharmacist interventions was of good quality, adequate, 
appreciated by the patients, and feasible in the daily life of community 
pharmacies. It resulted in improved s.c. injection technique and knowledge, 
despite high baseline patient skills. The home visits with the direct observation 
technique (DOT) were valuable in determining patient skills. Patients are 
capable of managing s.c. injection therapies in a satisfactory way and with 
high compliance if adequate assistance is provided. 
 
 Overall, we confirmed our hypothesis that intensive pharmaceutical care for 
outpatients self-injecting LMWH resulted in more safety (objective assessment 
of the s.c. injection technique during the DOT), but we had to reject our 
assumptions of improved compliance, more satisfaction, and fewer 
complications. 
 
 Our recommendations for daily practice are:  
(1) offering each person with a prescription for an outpatient s.c. injection 
treatment written information (leaflet, manual), application aids (alcohol 
swabs, sharps collector), and oral instructions (being the pivotal 
intervention in improving patients’ s.c. injection technique) 
(2) the first self-injection should occur in the presence of a health-care 
professional to ensure proper injection technique (at the patient’s own 
individual injection time) 
(3) injection training into a ‘phantom’ and further injections in the presence 
of or administered by a pharmacist are very supportive tools and should 
be applied if the patient requires lots of effort or has discomfort 
(4) potential needle phobia and handling difficulties should be kept in mind 
General introduction 
 18
1 General introduction 
1.1 Anticoagulants 
1.1.1 Thrombosis and embolism 
Arterial (e.g., ischemic stroke, myocardial infarction) and venous thromboses (e.g., 
deep vein thrombosis (DVT) and subsequent pulmonary embolism (PE)) are 
important diseases causing significant morbidity, mortality, and costs. The average 
annual incidence of venous thromboembolism (VTE) is approximately 1 person per 
1,000, and this increases with age. Despite appropriate treatment, thrombosis recurs 
frequently, at a rate of approximately 7% at 6 months. Death occurs in approximately 
6% of DVT and 12% of PE patients within 1 month [1]. Only about 20% of DVT are 
symptomatic [2]. There is strong evidence indicating that appropriately used VTE 
prophylaxis has a positive benefit-to-risk ratio, and is highly efficacious and cost-
effective. Without thromboprophylaxis, 10-40% of the medical or general surgical 
patients, 20-50% of stroke patients, 40-60% of patients following major orthopedic 
surgery, and 40-80% major trauma patients would have a hospital-acquired DVT [3].  
Under certain circumstances, each of us can be at risk for a thrombosis or embolism. 
There is a very wide range of risk factors covering inpatients and outpatients as well 
as unstable (intensive care unit) and stable patients. Examples are:  
 trauma, orthopedic, general surgical, or medical patients (e.g., bed rest, acute 
medical illness) 
 acquired risk factors, such as increasing age, previous VTE, heparin-induced 
thrombocytopenia (HIT) type II, long-distance travel, immobility, pregnancy, 
and lifestyle (e.g., obesity, smoking) 
 inherited conditions, such as thrombophilia 
 certain illnesses, such as cancer, varicose veins, diabetes mellitus, 
hyperlipidemia, and hypertension 
 certain medications, such as estrogen-containing oral contraceptives or 
hormone replacement therapy, selective estrogen receptor modulators, 
erythropoiesis-stimulating agents, and cancer therapy (e.g., chemotherapy, 
radiotherapy, thalidomide, tamoxifen) 
The individual risk increases with the accumulation of single risk factors [3-19]. 
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1.1.2 Antithrombotic drugs 
To date, the orally taken vitamin K antagonists (VKA) are, together with the 
parenteral administered unfractionated heparins (UFH) and low-molecular-weight 
heparins (LMWH), still the most frequently used anticoagulants [20]. LMWH are 
usually used for the initial treatment of arterial or venous thromboembolisms. In 
contrast, oral anticoagulants are prescribed for long-term use [7]. Due to their 
parenteral administration, long-term treatment with LMWH is only seen with 
contraindications to VKA (e.g., pregnancy) [18] or where studies showed better 
outcomes with LMWH compared to VKA (e.g., cancer) [3, 21]. Arterial thrombi are 
treated with antiplatelet agents, whereas anticoagulants are used for the prevention 
and treatment of VTE [7]. Table 1 gives an overview of the antithrombotic drugs 
licensed in Switzerland with their mode of actions diagramed in Fig. 1. Examples of 
antithrombotic drugs which are not available in Switzerland are the coumarin 
derivative warfarin, the thienopyridin derivate ticlopidin, the LMWH tinzaparin, the 
oral direct thrombin inhibitor Pradaxa (dabigatran etexilate), and the parenteral 
administered direct thrombin inhibitor Argatra (argatroban). The first oral direct 
thrombin inhibitor Exanta (ximelagatran) had been withdrawn from the market due to 
hepatotoxicity [7]. 
 
There is a need for new antithrombotic drugs that are characterized by similar 
effectiveness but lacking the limitations of the well-established heparins (e.g., 
parenteral administration, risk of HIT type II), VKA (e.g., inter- and intraindividual 
pharmacokinetics, need of close monitoring, narrow therapeutic window, high 
potential for drug-drug and drug-food interactions, delayed onset of action, delayed 
offset of action due to long half-lives of 10 to 160 hours), and antiplatelet agents 
(e.g., resistance, metabolic activation, delayed offset of action due to active 
metabolites) [7, 20, 22].  
A ‘perfect’ anticoagulant would have the following attributes: oral administration, 
simple dosing regime, fixed dosing, rapid onset and offset of action, predictable 
pharmacokinetics, wide therapeutic window, low potential for interactions, no need 
for routine monitoring, direct inhibition of a clotting factor (no need for a plasma 
cofactor such as antithrombin), no immuno-allergic reactions, high effectiveness, and 
good tolerance [22]. Very active research on novel agents is ongoing in this field. 
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Examples of agents in advanced stages of clinical testing (phase II/III trials) are 
edoxaban and betrixaban (direct oral factor Xa inhibitors), otamixaban (parenteral 
administered direct factor Xa inhibitor), bemiparin and semuloparin (newer ultra-low-
molecular-weight heparins), tecarfarin (VKA), as well as the thienopyridin derivates 
cangrelor and elinogrel. Oral direct factor Xa and thrombin inhibitors are in the most 
advanced stages of development. It is likely that new antithrombotic drugs and new 
classes of antithrombotic drugs will be approved in the next few years and that their 
spectrum of indications will continuously be enlarged. Nevertheless, the aim of 
replacing VKA and LMWH might not be reached very soon due to the long-lasting, 
extensive, and well documented experience with these medications, their 
comparatively low prices, and lack of specific antidotes for the new antithrombotic 
drugs [7, 20, 22, 23].  
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Table 1 Approved anticoagulants and antiplatelet agents in Switzerland (2011) [20, 24, 25] 
type of inhibition compound class innovator drug 
route of ad-
ministration 
ORAL ADMINISTRATION 
vitamin K antagonists 
coumarin derivatives 
 Marcoumar (phenprocoumon) 
 Sintrom (acenocoumarol) 
 
oral 
oral 
 Aspirin cardio (acetylsalicylic acid) 
 Asasantin retard (dipyridamol, acetylsalicylic acid) 
 DuoPlavin (clopidogrel, acetylsalicylic acid) 
 Brilique (ticagrelor) 
oral / (i.v.) 
oral 
oral 
oral 
indirect inhibition 
antiplatelet agents 
thienopyridin derivates 
 Plavix (clopidogrel) 
 Efient (prasugrel) 
 
oral 
oral 
direct inhibition factor Xa inhibitors 
 Xarelto (rivaroxaban) 
 Eliquis (apixaban) 
oral 
oral 
continued next page 
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type of inhibition compound class innovator drug 
route of ad-
ministration 
PARENTERAL ADMINISTRATION 
factor Xa inhibitors 
 Arixtra (fondaparinux; synthetic pentasaccharide) 
 Orgaran (danaparoid; heparinoid) 
s.c. 
s.c. / i.v. 
unfractionated heparins 
 Liquemin (natrium heparinate) 
 Calciparine (heparinum calcicum) 
 
s.c. / i.v. 
s.c. / i.v. 
combined factor Xa and thrombin 
inhibitors 
low-molecular-weight heparins 
 Fragmin (dalteparin) 
 Clexane (enoxaparin) 
 Fraxiparine / Fraxiforte (nadroparin) 
 Sandoparin (certoparin) 
s.c. / (i.v.) 
indirect inhibition 
antiplatelet agents 
glycoprotein (GP)-IIb/IIIa inhibitors 
 ReoPro (abciximab) 
 Aggrastat (tirofiban) 
 Integrilin (eptifibatid) 
 
i.v. 
i.v. 
i.v. 
direct inhibition thrombin inhibitors 
recombinant hirudins / hirudin derivatives 
 Refludan (lepirudin) 
 Angiox (bivalirudin) 
 
i.v. 
i.v. 
i.v. Intravenous; s.c. Subcutaneous 
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Fig. 1 Diagram of the plasmatic coagulation with the targets of the various anticoagulants and antiplatelet agents. Adapted from [26] 
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1.2 Subcutaneous injection therapy 
1.2.1 Pre-filled syringes and related systems  
Most biopharmaceuticals such as proteins, peptides, vaccines, antibodies, heparins, 
and antisense oligonucleotides are macromolecules. To date, most of these have to 
be administered parenterally (subcutaneous (s.c)., intravenous (i.v.), or intramuscular 
(i.m.)). Their oral bioavailability is marginal due to their characteristic large molecular 
size, high pre-systemic degradation, and physicochemical characteristics (e.g., 
hydrophilicity) [27].  
International conferences on pre-filled syringes with key speakers from the 
pharmaceutical industry, manufacturers, and researchers emphasize the rising 
demand for pre-filled syringes in the recent years [28, 29]. It is estimated that 2 billion 
pre-filled syringe units worth up to 2.5 billion US dollars were sold in 2009. For both 
new and existing products, there is a trend away from vials/ampules and towards 
pre-filled injection systems (e.g., glass and plastic syringes, pens, auto-injectors, 
including refills). They are the format of choice for many parenterally administered 
drugs as they are ready-to-use. The sector has shown growth of 10-15% in recent 
years, forming one of the fastest-expanding sectors in the pharmaceutical industry. A 
broad range of compound classes are administered with pre-filled syringes or related 
systems, such as vaccines, monoclonal antibodies, hormones, anti-infectives, anti-
inflammatory agents, hematological agents, erythropoietin products, obstetric agents, 
pain relievers, insulins, interferons, interleukins, or biosimilars. These devices are 
therefore used in the treatment of different diseases, including multiple sclerosis, 
rheumatoid arthritis, immunological disorders, diabetes mellitus, infectious diseases, 
cancer, osteoporosis, and hematological or hormone therapies. As the number of 
products licensed in pre-filled injectables increases, it is expected that the pre-filled 
drug delivery market will expand steadily and be worth up to 5.5 billion US dollars in 
2025  [30]. The market for pre-filled syringes and related systems is also of interest to 
generic pharmaceutical companies: Filgrastim, for example, is used for the treatment 
of neutropenia due to chemotherapy or a human immunodeficiency virus (HIV) 
infection. Pre-filled syringes of Filgrastim are available from 4 different 
pharmaceutical companies [24]. 
General introduction 
 25
1.2.2 Low-molecular-weight heparin devices 
In Switzerland, all LMWH and fondaparinux are administered s.c. with pre-filled 
syringes (Fig. 2). Post-injection needle guards have recently been developed for the 
prevention of needle stick injuries and the transmission of infectious diseases such 
as hepatitis or HIV. These syringes increase comfort as correctly installed safety 
systems make sharps collectors no longer mandatory and the used syringes can be 
disposed of in the garbage. Post-injection needle guards are activated either 
mechanically using physical effort (Fraxiparine / Fraxiforte, Fragmin) or triggered 
automatically when the syringe has been emptied by pressing the plunger all the way 
down (Clexane, Arixtra) (Fig. 3).  
 
The protective shield of Fraxiparine and Fraxiforte is securely locked once a clicking 
sound is heard after sliding it over the needle. The mechanism is poorly marked and 
positioning the guard properly requires considerable force and coordination. One has 
to be aware that patients are exposed to an increased danger of needle stick injuries 
when the needle guard is activated but has not been locked, as protection is 
assumed but not given.  
Fragmin is equipped with a needle-trap: The red needle-trap is folded toward the side 
by 50-80 degrees prior to remove the needle cap. After the injection, the needle is 
secured by placing the trap on a firm surface using one hand. The trap is then 
pushed down and bent by more than 45 degrees until the needle locks into the red 
plastic part by a clicking sound.  
While keeping the thumb grip pressed when withdrawing the needle from the skin 
fold, the protective shield of Clexane comes out and automatically covers the needle. 
In contrast, releasing the thumb grip of Arixtra withdraws the needle automatically 
from the skin and retracts it into the protective shield where it is locked. The safety 
systems of Clexane and Arixtra are only activated when the whole volume has been 
injected. Sandoparin is not equipped with any special safety system [31]. 
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Fig. 2 LMWH and Arixtra pre-filled syringes in Switzerland (2011) 
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Fig. 3 Activated post-injection needle guards of used LMWH and Arixtra syringes 
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1.2.3 Subcutaneous injection technique 
In the past, great effort has been made to analyze techniques and device 
characteristics which make an s.c. injection as comfortable as possible (e.g., air 
bubble, allowing the alcohol to dry before inserting the needle, skin fold, injection 
angle, aspiration prior to injection, injection duration, waiting before withdrawing the 
needle, application of ice or pressure at the site of injection; syringe and needle size, 
injection volume, changing the needle prior to injection) [32-34]. 
There is no consensus about the preferable injection site for the administration of 
LMWH. The abdominal skin has a thicker s.c. tissue, is easily accessible, and has a 
large surface area [33]. Nevertheless, there is a trend towards injections into the 
thigh, with the intention of reducing the risk of hematomas in the abdominal wall and 
rectus sheath ─ rare but regularly published complications after s.c. injections into 
the abdomen [35].  
Beside the selection of the individual’s appropriate injection site, a proper injection 
technique contributes to a safe and positive outcome. The individual steps of an s.c. 
injection can be divided into four aspects:  
(1)  to ensure that the injection is s.c. and neither intracutaneous nor i.m.: 
pinch a skin fold, insert the full length of the needle perpendicular into the 
skin (minimal injection angle of 45°), and release the skin fold after 
withdrawing the needle 
(2)  to ensure that the whole volume is injected: do not remove the air bubble 
(preferably place the air bubble above the fluid level), and wait a second 
before and keep the thumb grip pressed when withdrawing the needle (to 
ensure that no fluid is pulled out by an early discontinuation) 
(3)  to avoid needle stick injuries: put the sharps collector within easy reach, 
remove the needle shield horizontally using both hands, do not put down 
the bare needle, do not recap, and dispose of the syringe immediately after 
withdrawing the needle 
(4)  to ensure a hygienic injection: wash or disinfect the hands right before 
injection (and not in advance), disinfect the skin area (a single wipe is 
sufficient; very hairy skin can be cleansed by a single wipe each with the 
front and back sides of the alcohol swab; by rubbing, the contamination is 
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just moved around), wait for the alcohol to evaporate (skin not shiny 
anymore, i.e. allow the alcohol to react and in doing so, avoid burning), 
avoid contact with disinfected skin area (i.e. through clothes), do not put 
down or touch the bare, aseptic needle, do not wipe off a drop on the 
aseptic needle (but shake it off; leaving the drop might provoke burning), 
and puncture into the cleansed skin area 
Other aspects contribute to patient comfort and to a reduction in adverse drug 
reactions, such as having the materials within easy reach, making an unhesitant 
puncture, slowly injecting, swabbing the skin area after injection (rubbing might 
provoke hematoma), and use of a plaster [31-34]. 
 
Self-injections in an outpatient setting are of increasing importance as they 
strengthen patient’s responsibility for his/her own disease management, grant greater 
independence, and reduce costs by minimizing visits to the general practitioner (GP), 
hospital, or nursing service. It has been perceived that pharmacists can also play a 
crucial role in appropriate patient education, training, and support [36]. Good patient 
education has not only an impact on a proper injection technique, compliance, and 
clinical outcome, but is also of economic importance: Rebif (recombinant interferon 
beta) for example is prescribed for the treatment of multiple sclerosis. It is available 
as pre-filled syringe or auto-injector and can be administered s.c. on an outpatient 
basis. Following the usual treatment recommendations (injections three times weekly 
with 184 Swiss francs per pre-filled syringe), the overall costs amount to 28,704 
Swiss francs per year [24].  
 
1.3 Handling difficulties and drug use problems with medication 
Reasons for handling difficulties and drug use problems with medication are diverse 
and may lead to dosing errors or non-compliance. They are either related to the 
medication, packaging, or device (e.g., small size, poor design, poor quality, bad 
markings, complicated to use, physicochemical characteristics handicapping proper 
administration) or to the patient’s impairment (e.g., poor fine motor skills, impaired 
vision or hearing, cognitive impairment, deficiency in force). Force impairments might 
be caused by the patient’s position when administering the medication, an injury, or 
illnesses such as arthritis, gout, diabetes mellitus, stroke, and Parkinson’s disease. 
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With the continuous aging of the population and the promotion of outpatient 
therapies, the prevalence of handling difficulties and drug use problems with 
medication is likely to increase [37]. In particular, the use of pre-filled injection 
systems, inhalers, and spray bottles, the application of nose and eye drops, and the 
splitting of tablets are challenging [38-41]. These pitfalls have been recognized and 
led to the development of application aids (e.g., holding chambers or spacers, disk 
inhalers instead of metered dose inhalers, tablet-splitting devices, rotation aids for 
opening screw caps, dosing syringes, aids for positioning the eye drop, pill 
organizers) or the ergonomic optimization of existing devices (e.g., large font sizes, 
embedded magnifying glasses, or colour changes for the dosage display, larger 
devices, single-use or automatic pens, tactile signals (vibrations), acoustic feedback) 
[31, 38, 40-43]. 
The maximal pinch strength of women under 60 years of age is over 60 Newtons (N), 
men achieve approximately 100 N (1 N corresponds roughly to 100 grams). Maximal 
forces decrease with age, resulting in 40 N in men and less than 10 N in women 
aged 90 years or more [38, 42]. Forces needed to handle the medication, packaging, 
or device range from 4 to 80 N [38-40, 44].  
As low-threshold facilities, community pharmacies are suitable for patient education, 
training, and support. Patients seeking assistance would rarely communicate their 
handling difficulties or drug use problems, but appreciate any help. Pharmacists play 
a crucial role in recognizing and preventing potential handling difficulties by offering 
an extensive first instruction, by monitoring patient’s first self-administration, and by 
regularly monitoring patient’s self-administrations under daily life conditions to ensure 
a proper technique. Thereby, the pharmacist can determine the patient’s most 
appropriate device, and consult the GP if needed. To offer the best support, it is 
recommended that community pharmacies are always equipped with the latest 
placebo devices and education materials [38-41, 43, 44]. 
 
1.4 Pharmaceutical Care 
Definitions 
Pharmaceutical Care (PC) is defined as ‘the responsible provision of drug therapy for 
the purpose of achieving definite outcomes that improve a patient’s quality of life’ 
[45]. These outcomes aim at curing a disease, minimizing or eliminating symptoms, 
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arresting or slowing a disease progression, and at preventing a disease or 
symptoms. Suboptimal outcomes might arise from inappropriate prescribing, 
inappropriate delivery (e.g., drug not available, incorrect or no patient education), 
inappropriate patient behaviour (e.g., non-compliance, handling difficulties, drug use 
problems), patient idiosyncrasy, or inappropriate monitoring (e.g., no verification of 
effectiveness). A drug-related problem (DRP) is ‘an event or circumstance involving 
drug treatment that actually or potentially interferes with the patient’s experiencing an 
optimum outcome of medical care’ [45]. They include untreated indications, no 
indication for treatment, inappropriate medication (i.e., no effect, better alternative 
with respect to patient characteristics or economic considerations), over- or 
underdosage, failure to receive the medication as intended (e.g., non-compliance, 
drug use problem, handling difficulties), adverse drug reactions, and drug 
interactions. [45-47].  
 
Pharmaceutical care process 
PC concentrates on the process of ‘drug use’, and is characterized by its dynamic 
and continuous nature. It involves cooperation between the pharmacist and the 
patient and aims at developing an individualized, patient-centered, and goal-oriented 
treatment plan to optimize safety and effectiveness. The PC process implies an 
active participation of the patient in making decisions concerning his/her treatment 
plan. It consists of four levels (Fig. 4):  
(1) assessment of patient needs and identification of potential or actual DRP 
(2) design and implementation of a care plan: provision of appropriate 
interventions and patient education to solve and prevent DRP as well as to 
achieve therapeutic goals 
(3) patient action 
(4) periodic outcome evaluation: monitoring of the progress in meeting therapeutic 
goals and reassessment for new DRP [45, 47-49] 
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Fig. 4 The pharmaceutical care process ─ continuous teamwork between 
pharmacist, patient, and physician aiming at optimal patient outcomes regarding 
safety and effectiveness [45-49] 
DRP Drug-related problems; PC Pharmaceutical care 
 
Pharmaceutical care ─ a pharmacist’s duty 
The International Pharmaceutical Federation (FIP) and World Health Organization 
(WHO) have recently published the ‘Joint FIP/WHO guidelines on good pharmacy 
practice: standards for quality of pharmacy services’ [50]. These guidelines comprise 
PC as a challenging duty of pharmacists, which goes beyond the conventional role of 
preparing and dispensing drugs. Clinical pharmacy includes PC and can be 
performed irrespective of the setting by either a hospital or community pharmacist 
[51]. Transitions between two settings, in particular discharge from hospital to the 
ambulatory setting, pose critical and vulnerable phases susceptible to DRP. As 
physicians often fail to communicate essential elements when prescribing new 
medications [52] and after discharge patients often visit their community pharmacy 
before seeing their GP, hospital and community pharmacists play important roles in 
ensuring the continuity of care through a seamless transition from inpatient to 
outpatient care [53]. The National Health Service (NHS) in the United Kingdom has 
perceived the need to act and commenced a New Medicine Service (NMS) in autumn 
2011. This service provided by community pharmacists supports patients with long-
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term conditions receiving a newly prescribed medication. Initially, the service is 
focused on particular patient groups and conditions, including the treatment with oral 
anticoagulants and antiplatelet agents [54].  
Through the prevention and solution of DRP leading to increased safety and 
effectiveness, pharmacists may contribute to improved outcomes and to a reduction 
of costs [45]. An extensive review on the effectiveness of PC, however, revealed 
inconsistent results [55]. The multidisciplinary communication between pharmacist, 
patient, and physician is not only for the direct benefit of the patient, but may also 
promote closer collaboration between health-care professionals [45, 47]. Last but not 
least, one has to be aware that the provision of PC implies direct contact with the 
patient, and therefore cannot be offered by mail-order pharmacies [39]. 
 
1.5 Compliance 
Definitions 
A patient is compliant, if he/she administers or takes properly the correct medication 
at the prescribed time, in the prescribed dosage, over the prescribed therapy duration 
without unintentional combinations [43, 56]. Poor compliance is a worldwide 
phenomenon of striking magnitude with a prevalence of about 50%; the degree of 
non-compliance has been shown to be disease- and time-dependent [57-63]. 
Consequences of non-compliance are poor clinical outcomes, increased mortality, 
and increased health-care costs (e.g., emergency department visits, hospital 
admissions, intensified pharmacotherapy, increased morbidity, waste of medical time 
and waste of medication dispensed but not taken) [56, 60-67]. Table 2 gives an 
overview of the terminology used in the literature to describe patient involvement in 
decision-making about his/her treatment plan and his/her behaviour when following it. 
 
Table 2 Definitions concerning patient involvement in decision-making about his/her 
treatment plan and their behaviour when following it 
compliance  Extent to which a patient follows the health-care professional’s 
advice and takes the treatment [61] 
 Characteristics: passive, obedient patient [61]; measurable 
adherence  Extent to which a person’s behaviour ─ taking medication, 
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following a diet, and/or executing lifestyle changes ─ corresponds 
with agreed recommendations from a health-care professional [62] 
 Characteristics: refined definition of ‘compliance’, intending to 
break with the picture of the passive, obedient patient [43, 68]; 
measurable 
concordance  Agreement between the patient and health-care professional, 
reached after negotiation that respects the beliefs and wishes of 
the patient in determining whether, when, and how their 
medication is taken, and (in which) the primacy of the patient’s 
decision (is recognized) [69] 
 Characteristics: process of shared, informed decision-making; 
partnership approach [61]; not measurable 
persistence  Duration of time from initiation to discontinuation of therapy [70] 
 Period of time being compliant [43]; measurable 
 
Compliance behaviour 
Ten types of non-compliance are known:  
(1) ‘parking place effect’: non-acceptance of the treatment (no treatment or 
discontinuation shortly after filling the prescription) leading to no or 
reduced effect 
(2) ‘drug holiday’: break in the persistence (e.g., due to economic reasons) 
leading to potential rebound effects or development of resistances 
(3) ‘toothbrush effect’: a non-compliant patient becomes compliant shortly 
before the next visit with the GP potentially masking non-compliance 
(satisfying short-term laboratory-chemical markers, but suboptimal long-
term values) 
(4) compliant intake/use of a wrong medication 
(5 ─ 7) dosing errors leading to reduced effects, potential toxic effects, or 
adverse drug reactions: over-, under-, or erratic dosage 
(8) wrong administration frequency 
(9) wrong therapy duration 
(10) polypharmacy with additional, over the counter (OTC) medications 
leading to potential drug interactions [43, 56] 
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Potential barriers influencing compliance include:  
 patient-related factors, such as age, lifestyle, knowledge, attitudes, beliefs, 
expectations, and mental or physical impairments 
 social and economic factors, such as poverty and lack of social support 
 health-care system-related factors, such as poor patient/health-care 
professional relationship, poor medication distribution, lack of knowledge of 
health-care professionals, short consultations, and lack of electronic 
information-technology systems (data sharing across health-care 
professionals and care settings) 
 condition-related factors, such as severity of symptoms and degree of 
disability 
 therapy-related factors, such as complex medication regimens, long-term 
treatment, previous treatment failure, and adverse drug reactions [62, 64, 65, 
67] 
In order to assess potential barriers and intervene adequately, it is essential to 
identify patient’s beliefs about his/her treatment (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Balancing the benefits (necessity of treatment) and drawbacks (e.g., concerns 
about adverse drug events, dependence) of a medication determine patient’s 
likelihood to follow a treatment plan [71, 72] 
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Another classification of compliance behaviour is the differentiation between 
intentional and unintentional non-compliance: 
 
 Intentional non-compliance is associated with patient beliefs and includes 
denial of the disease, refusal of the treatment, or changing of dosage without 
prior consultation [43, 56]. In the study of Jackevicius et al., for example, 87% 
of patients did not fill their first prescription for an injectable anticoagulant for 
the secondary prevention after acute myocardial infarction [73] 
 
 Unintentional non-compliance is not planed and more diverse. It comprises 
forgetfulness, bad communication, complex treatment plans, or handling 
difficulties [43, 56]. Unintentional non-compliance seems to be three times 
more prevalent than intentional non-compliance with forgetfulness being a 
major factor [74]. 
 
Strategies to improve compliance 
Strategies include multifaceted, patient-tailored interventions (Fig. 6), including 
patient information (oral and written) and education [75], communication skills, active 
listening, motivational interview depending on the patient’s stage of self-change 
readiness [76], telephone follow-up, active patient involvement such as self-
monitoring, use of application aids, electronic reminder systems, pill organizers, 
rewards for patients and health-care professionals for improved patient outcomes, 
collaborative team approaches involving multiple health-care professionals, and 
simplification of medication regimens (e.g., fixed combinations at the cost of flexibility 
concerning choice of drug substances and dosages) [43, 57, 60, 62, 64-67, 77].  
Facing the wide range of factors potentially leading to non-compliance and their 
complex interplay, appropriate medication use remains a challenge for both patients 
and health-care professionals [60, 65] and to date, the effects of the interventions 
remain sparse [57]. Strategies to improve compliance should be considered by 
insurers, government payers, and patients, as long as intervention costs do not 
exceed the estimated health-care cost savings. Among others, pharmacist-led 
counselling has been perceived to be an appropriate approach [66, 67]. 
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Fig. 6 Examples of patient-tailored interventions to counteract intentional and 
unintentional non-compliance [43, 56, 60, 62, 64, 65, 78, 79] 
 
 
Methods to measure compliance behaviour 
The response rates to treatments are individual (e.g., due to polymorphisms, non-
responders), which limits the assessment of patient’s compliance by clinical and 
laboratory-chemical markers (e.g., blood pressure, pulse rate, blood glucose, HbA1c, 
peak flow, international normalized ratio (INR)) [56].  
 
Indirect measurement methods to assess patient’s compliance comprise patient self-
reports [80-82], use of diaries, ‘pill count’ or ‘syringe count’ (determination of ‘taking’ 
compliance by counting the number of residual tablets or by calculating the number 
of missing used syringes, respectively), determination of residual drug volumes in 
used syringes, examination for evidence of recent s.c. injections [83], attendance at 
appointments (visits with GP, (re)filling of prescription), or estimation of the effect. 
These methods are simple and mostly cheap at the cost of reliability [56, 62, 65, 68, 
84]. Electronic compliance monitoring devices (ECMD) like medication event 
monitoring systems (MEMS®) record electronically the ‘taking’ and ‘timing’ 
compliance of a single medication. Electronic multidrug compliance monitoring (e-
MCM) is a further development allowing the control of the intake frequency of several 
medications at a time [85]. The market for electronic pill organizers is growing rapidly. 
Some of them are equipped with acoustic or visual signals or generate a text 
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message [43, 62]. These new technologies, however, are very expensive and not 
applicable for pre-filled syringes.  
 
Direct measurement methods to assess patient’s compliance involve medication 
administration under supervision and the testing of blood or urine samples for agents, 
its metabolites, or marker substances (e.g., therapeutic drug monitoring (TDM)). The 
direct methods are more reliable on the one hand, but more time-consuming, 
expensive, and not applicable to all medications on the other hand [56, 62, 65, 68, 
84].  
 
To date, there is no established gold standard to measure compliance behaviour [62, 
78, 84]. The method of choice depends on the type of non-compliance suspected. A 
multi-method approach combining self-reports and objective measures is the current 
state-of-the-art [62]. 
 
Therapeutic coverage 
There is no universally valid adequate degree of compliance existing that would 
assure the achievement of definite outcomes. The required extent depends on the 
pharmacokinetic and pharmacodynamic properties of the individual medication. The 
time in the therapeutic window (= therapeutic coverage) is crucial. The half-life and 
duration of action determine if a medication is a ‘forgiving drug’ (e.g., acetylsalicylic 
acid) or a ‘non-forgiving drug’ (e.g., immunodepressants, HIV medication) [43, 56, 68, 
86, 87]. 
 
1.6 Rationale and aims of the thesis 
Pre-filled syringes are increasingly being used for the self-administration of various 
medications in ambulatory care. They constitute one of the fastest growing markets 
in drug delivery. One would expect that poor patient acceptance, including needle 
phobia, would impede successful use and that compliance could be a major issue. 
Literature on drug use problems and compliance with s.c. injection therapies in 
outpatients is rare. Previous studies have only investigated specific patient 
populations recruited from selected clinics or hospitals receiving educational 
programs. However, neither studies using a heterogeneous patient population 
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receiving standard care nor studies that were controlled or examined the feasibility of 
the interventions in daily life were identified.  
 
Therefore, this thesis aimed to identify drug use problems and handling difficulties 
with pre-filled syringes and to evaluate the impact of pharmaceutical care on 
outpatient s.c. injection therapies. LMWH proved to be a convenient tool to meet our 
objectives: To date, they are prescribed frequently and mostly for short-term 
outpatient treatment; it is a comparatively cheap s.c. injection therapy with high 
application frequencies; and is used in a heterogeneous, relatively healthy 
population.  
 
As key steps towards fulfilling these aims, we elaborated the following projects in this 
thesis: 
 
Handling difficulties and drug use problems with pre-filled syringes 
Handling difficulties and drug use problems with medication can either be attributed 
to patient impairments or to the medication itself, its packaging, or device. The 
consequences are suboptimal outcomes due to dosing errors and non-compliance. 
With the continuous aging of the population, the promotion of outpatient therapies, 
and the fast growing market for pre-filled syringes, handling difficulties and drug use 
problems are increasing in importance. In order to recognize and prevent DRP in the 
context of pharmaceutical care, it is crucial to get a detailed overview of their 
characteristics, prevalence, and variety.  
 
Project A: Pitfalls in patient self-management of subcutaneous drug 
application: removal of rubber protection caps from ready-to-use 
syringes 
The objective of this project was to investigate one single handling 
difficulty, which ─ to our knowledge ─ had not been reported in the 
literature so far. We aimed to compare subjectively and objectively 
measured pull-off forces required to remove the rubber protection cap 
(needle shield) of commercial LMWH pre-filled syringes.  
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Project B:  Drug use problems with self-injected low-molecular-weight 
heparins in primary care 
It was the aim of this project to record the spectrum of drug use 
problems, patient satisfaction, and patient compliance of pharmacy 
customers treated with LMWH under daily life conditions. The results 
should highlight potential areas for improvements in patient care 
through specific interventions. Additional aims were to identify 
differences in problems arising due to the choice of injection site 
(abdomen vs. thigh) and to determine residual drug volumes in the used 
syringes. 
 
Outpatient low-molecular-weight heparin therapy 
The provision of patient-centered, pharmaceutical services by community 
pharmacists are needed in order to justify their future role in the health-care system 
and to fulfill the community’s expectations. The influence of pharmaceutical care on 
asthma, elevated lipid levels, hypertension, and diabetes has been investigated, but 
knowledge of the effectiveness of community-pharmacy-based interventions on 
problems in self-administering s.c. injection therapies is lacking. 
 
Project C:  Self-management of outpatient low-molecular-weight heparin 
therapy: impact of pharmaceutical care 
Our aims in this study were:  
(1) the development of a standard operating procedure (SOP) for 
the first instruction in the s.c. injection technique given by a 
community pharmacist and the subsequent pharmaceutical care 
provided during the outpatient LMWH therapy 
(2) the comparison of intensive pharmaceutical care vs. standard 
care in both a clinical setting (hospital wards under study 
conditions) and in a daily life setting (community pharmacies 
following their daily routine) 
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2 Handling difficulties and drug use problems with pre-
filled syringes
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2.1 Project A:  
Pitfalls in patient self-management of subcutaneous drug 
application: removal of rubber protection caps from ready-to-
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Sirs,  
Outpatient subcutaneous therapies are becoming more and more common, such as 
the use of low-molecular-weight heparins (LMWH) for prophylaxis or for the 
therapeutic treatment of thromboembolisms, multiple sclerosis, arthritis, anemia, or 
female infertility. Based on reports from patients and nurses indicating that some 
ready-to-use syringes require a concerted effort to remove the rubber protection cap, 
we decided to evaluate cap removal forces of commercial LMWH pre-loaded 
syringes as we were unable to find an ISO-norm from such syringes nor studies on 
this topic. 
 
Three methodological approaches was used: (1) self-assessment by a study 
population, (2) simultaneous observer’s assessment, and (3) mechanical pull-off 
tests. 
In parts (1) and (2) of our study, we analyzed Clexane (enoxaparin; old device), 
Fragmin (dalteparin), and Fraxiparine (nadroparin), three widely prescribed LMWH 
products in Switzerland. The study population included 68 persons (age range 19-86 
years, median age 29 years), of whom 34 were pharmacy students, 18 were 
hospitalized orthopedic patients, and 16 were pharmacy customers. Persons with 
obvious disabilities of the upper extremities were excluded. One syringe of each 
brand within its expiration date was given to each of the subjects in randomized 
order. In part (1), subjects rated the force needed to remove the rubber protection 
cap using a visual analog scale (VAS). In part (2), the observer rated the effort 
needed to remove the cap as: (1) no effort needed, (2) effort needed, or (3) can not 
remove the protection cap. In part (3), the pull-off forces were investigated on a 
standard mechanical testing machine. The custom-designed holding fixture allowed 
an axial pull-off of the cap, measured in Newtons (N), at a constant speed without 
shear forces. In addition to the syringes used in parts (1) and (2), we enlarged the 
study sample with Arixtra (fondaparinux), Clexane (new device with an automatic 
safety system), and Sandoparin (certoparin), which meant that our study included the 
most important brands. Of each brand, 20 syringes within the expiration date were 
tested in randomized order (two different lots of ten syringes per lot).  
 
Handling difficulties and drug use problems with pre-filled syringes 
 44
The results of part (1) of this study revealed that the removal of the rubber protection 
cap was not possible in five of 204 cases involving four subjects and two brands. 
Figure 1a shows significant differences between the VAS scores (ANOVA p<0.001; 
Tukey-B-test p<0.05 for pairwise differences between the mean values) and high 
interquartile ranges caused by highly individual self-estimations. The observer’s 
results from part (2) supported these findings (Fig. 1b). Measurements of the 
mechanical cap-pull-off forces (part 3) showed a large range of median forces 
(13.6─29.9 Newton) were needed to remove the rubber caps, with the highest forces 
needed for Fraxiparine and the old Clexane device (ANOVA p<0.001; Tukey-B-test 
p<0.05). Significant differences between different lots of the same brand were 
detected only with Fraxiparine (Fig. 1c). 
 
In conclusion, the mechanical cap-pull-off tests confirmed the results from self- and 
observer’s assessments, and important differences between brands were observed. 
The pull-off forces correspond roughly to the force needed to hold a narrow-neck 
plastic flask containing 1─3 l of water by pinching the neck between a finger and 
thumb. Medical staff should be aware of these possibly crucial handling difficulties 
and their consequences for successful therapy and compliance.  
 
Handling difficulties and drug use problems with pre-filled syringes 
 45
Tables and figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Determination of the pull-off forces needed to remove the rubber protection caps from ready-to-use syringes.  
continued next page 
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a Self-assessment using the visual anaolg scale: 0 = no effort/100 = enormous effort. Values are presented as the median and 
interquartile range (IQR): Fraxiparine 48.5 (49.75), Clexane old device 36.0 (44.5), Fragmin 14.5 (20.75). 
b Simultaneous observer’s assessment using three assessments (%): black portion of bar person can not remove the protection 
cap (Fraxiparine 4.41; Clexane old device 2.94; Fragmin 0), portion of bar with diagonal stripes person needs to make some effort 
(Fraxiparine 39.71; Clexane old device 19.12; Fragmin 2.94), open portion of bar person needs no effort (Fraxiparine 55.88; 
Clexane old device 77.94; Fragmin 97.06). 
c Mechanical pull-off tests (N) performed by a standard mechanical testing machine; each bar indicates one lot including ten 
syringes. Values are given as the median and IQR 
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2.2 Project B:  
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Abstract  
 
Purpose 
Outpatient subcutaneous therapies are becoming increasingly common. A literature 
search failed to find any studies on application problems pertaining to the self-
injection of low-molecular-weight heparins (LMWH) in a heterogeneous outpatient 
population under daily-life conditions. We therefore designed a study with the aim of 
recording drug use problems, patient satisfaction, compliance, problems arising from 
the injection site (abdomen vs. thigh), and residual drug volumes in pre-filled syringes 
used in self-injection therapy. 
 
Methods 
Patients were recruited in community pharmacies by 95 trained Master’s students in 
pharmacy. Data were collected during recruitment and by means of structured 
questionnaire-based telephone interviews that were carried out at the beginning and 
the end of the LMWH treatment. 
 
Results 
The median age of the 213 patients enrolled in the study was 54 years (interquartile 
range (IQR) 39─70 years); of these, 15.5% had their injections administered by a 
third person. The rate of self-reported non-compliance was 17.1%. At least one 
relevant problem was recorded in 85.0% of the cases. At the end of the treatment, 
38.9% of the patients stated self-administration of the injections required some effort. 
The preferred injection site was the thigh (68.5%). An overall mean residual drug 
volume ≥10.0% was detected for 3.9% of the patients. If residual drug was present, a 
median of 11.2% (IQR 8.6─17.6%) of the total drug volume had not been injected. 
Patients injecting into the thigh showed a higher risk of leaving residual medication 
(odds ratio 2.16, 95% confidence interval 1.04─4.51). 
 
Conclusions 
Most patients had drug use problems, whereas no clear factors were associated with 
non-compliance, the injection site (apart from residual drug), and discomfort or effort 
required (apart from prior injection use). 
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Introduction 
 
Low-molecular-weight heparins (LMWH) are frequently used for the prevention and 
treatment of venous thromboembolism [3, 5, 18]. There is strong evidence 
demonstrating the good benefit-to-risk ratio and cost-effectiveness of venous 
thromboembolism prophylaxis [3]. Treatments with LMWH are often started during a 
hospital stay or at hospital discharge and followed up by daily subcutaneous (s.c.) 
self-injections in an ambulatory setting for a period of time varying from days to 
weeks. Results from published studies demonstrate that home treatment of deep 
vein thrombosis with LMWH is at least as safe and effective as inpatient 
treatment─and may save costs and increase patient satisfaction [88, 89].  
Approaches involving outpatient s.c. therapies for the treatment of different diseases 
are becoming increasingly common. In addition to being used for the injection of the 
LMWH, pre-filled ready-to-use syringes are readily available for the treatment of 
multiple sclerosis (e.g., interferons), arthritis (e.g., methotrexate, tumor necrosis 
factor alpha blocker), anemia (e.g., erythropoietin), cancer (e.g., interferons), female 
infertility (hormones), hepatitis B and C (e.g., interferons) as well as for contraception 
(medroxyprogesterone acetate). Additional devices are pens, which are used by 
diabetic patients (insulin, exenatide) or for migraine treatment (e.g., sumatriptan), 
injectors, which are often used in the treatment of osteoporosis (recombinant 
parathyroid hormone analogue), or vials/ampules, where preparation is needed 
before injection (e.g., female infertility, cancer, multiple sclerosis and enfuvirtide in 
HIV treatment). A search of the literature failed to identify studies focusing on drug 
use problems and/or the practical aspects of s.c. self-administration beside the 
LMWH in an outpatient setting. Rather, most of the studies on the self-injection of 
other agents concentrated on other aspects of this therapeutic approach, such as 
pharmacokinetics, effectiveness, safety, and patient satisfaction. 
Discussions on the preferred injection site are ongoing, especially with LMWH [90-
93]. Case reports of hematomas in the abdominal wall and rectus sheath due to s.c. 
injections into the abdominal wall are rare, but appear regularly in the literature [94-
102]. Risk factors seem to be advanced age, female gender, polymorbidity, renal 
impairment, cough, therapeutic LMWH dosages, and concomitant use of 
anticoagulants. There is no expert consensus on the preferable injection site, often 
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not even within one hospital. Patients who have already received LMWH treatment in 
the past are especially irritated when they receive a complete new set of instructions. 
Even more confusing is the wording for the abdomen and thigh injection sites: for 
example, eight different terms pertaining to the abdomen and five descriptions of the 
injection in the thigh were found in Swiss package inserts and leaflets. Expressions 
such as “ventral, collateral region of the abdomen” or “outer upside of the thigh” are 
difficult to visualize, especially by the layperson. The injection sites “back of the 
upper arm” or the “gluteal area” are rarely used, as these sites are unsuitable for self-
injections. In addition to the injection site, a proper injection technique contributes to 
a safe and positive outcome, i.e., injecting slowly into a skin fold to reduce site pain 
and bruising [32, 33] as well as to ensuring that the injection is subcutaneous and not 
intramuscular. 
Little information on drug use problems and compliance with LMWH treatment in 
outpatients is available in the literature [83, 103-105]. Previous studies only 
investigated orthopedic patients recruited from selected clinics or hospitals. All of 
these study participants received educational programs that included instruction in 
the injection technique, performing their first self-injection in the presence of a 
medical professional (nurse or physician), and (occasionally) written information 
material or a video tape. Study sizes ranged from 40 to 214 patients. However, we 
were unable to find any study involving a heterogeneous patient population receiving 
standard care. 
 
We therefore designed a prospective cross-sectional study using pharmacy 
customers treated with LMWH as a convenient representative population receiving 
s.c. therapies with pre-filled syringes under daily life conditions. Our aim was to 
record drug use problems, patient satisfaction, and patient compliance. The results 
should highlight potential areas for improvements in patient care through specific 
interventions. The secondary aims were to identify differences in problems arising 
due to the choice of injection site (abdomen vs. thigh) and to determine residual drug 
volumes in the used syringes. 
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Methods 
 
Setting and study population 
 
Patients were recruited sequentially in community pharmacies by pharmacy students 
during their internship. Between January and May 2008, 95 Master’s students of the 
two German-speaking universities of Basel and Zurich were instructed to recruit and 
interview ambulatory LMWH patients. In advance, the students received: (1) a 
detailed oral study briefing and written information; (2) documents for data collection; 
(3) instructions in the s.c. injection technique, including clinical training by nursing 
staff. 
A broad range of inclusion criteria was deliberately chosen with the intention of 
reaching a varied sample of LMWH patients reflecting all aspects of daily life: 
outpatients aged ≥18 years, all brands of LMWH (pre-filled syringes), prophylactic or 
therapeutic use, new or long-term prescription, first or previous outpatient s.c. 
treatment, all therapy durations, self-injection or application by another person (e.g. 
family member, nursing service), and no comprehension difficulties due to language. 
 
Data collection 
 
Routine prescription validation by each community pharmacy (standard care) was 
performed when a LMWH was requested. The study was explained to the person 
bringing the prescription (the patients themselves or another person) and instructions 
were given on the s.c. injection technique if required. If the patient met the inclusion 
criteria and oral consent was obtained, written patient information and a sharps 
collector (E-safe) for the used syringes were delivered.  
 
Telephone interview 
 
At a pre-arranged date─either 1–3 days after the prescription was filled or at start of 
the LMWH treatment─an extensive structured questionnaire-based telephone 
interview was carried out. The trained students filled in the questionnaire by 
interviewing only the patient, even if the injections were carried out by another 
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person. The survey consisted of open questions wherever possible, and patients’ 
spontaneous answers were recorded. Multiple answers were accepted, but no 
answer suggestions were allowed. The reason for carrying out this telephone 
interview at an early point in the LMWH treatment was to evaluate drug use 
problems, the amount of effort required to self-inject, and discomfort at the beginning 
of the treatment. Self-estimations were assessed on two different scales: (1) an 11-
point scale to rate discomfort (0=very uncomfortable; 10=very comfortable) and (2) a 
4-point scale to assess the degree of effort required (1=no effort required at all; 
2=nearly no effort required; 3=sometimes effort required; 4=considerable effort 
required) and drug use problems in general. In addition, the interview gathered 
information on patient and medication characteristics, self-management, knowledge, 
quality of care, and patient satisfaction. If participants confirmed being impaired in 
their daily activities due to any kind of problem, pain, injury, or illness associated with 
the arm, shoulder, or hand, we rated the patient as being impaired in fine motor skills. 
 
Final interview 
 
After completion of the s.c. therapy, a short, structured questionnaire-based interview 
was carried out with each patient when he/she returned the sharps collector to their 
community pharmacy for professional disposal. The questions focused on the 
amount of effort required to maintain the treatment (none at any time; only in the 
beginning of treatment; occasionally; during the whole treatment period), on 
discomfort at the end of treatment, and on self-reported non-compliance. Exactly 
when this short interview took place depended on each individual’s treatment 
duration. Patients were instructed to return their sharps collector after 6 weeks if the 
treatment period was longer. 
The data collection was anonymized by assigning a code to each patient. 
Participants were asked to give oral consent each time they were contacted. The 
study protocol was approved by the local Ethics Committee of Basel (EKBB 95/07). 
 
Analysis of used syringes 
 
The returned sharps collectors were examined for the following: identification of 
patient code and syringe type; number of used syringes; number of syringes with 
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recapping (illegitimate replacement of the needle shield─sometimes called needle 
cap─after injection); number of syringes with a visible residual drug volume; amount 
of residual drug volume; number of syringes with a correctly installed safety device 
for the prevention of needle stick injuries after injection. 
Because the residual drug had often evaporated (especially in syringes without 
recapping), its volume could only be reliably determined by measuring the distance 
between the plunger and the end of the syringe barrel. Accordingly, the residual 
volume could be estimated by comparison with an unused syringe of the same type 
(taking the air bubble into consideration). To obtain this reference distance, we 
calculated the mean values of at least three syringes of each type. The mean 
residual drug volume (as a percentage) was defined as being equal to the calculated 
mean residual distance (percentage). Unused syringes were not included in this 
analysis. We considered a residual drug volume to be relevant if ≥10.0% of the total 
volume remained in the syringe. 
 
Statistical analysis 
 
The interview data sheets were processed with the automated form-processing 
software TELEform ver. 10.2 (Cardiff Software, Vista CA). To avoid potential errors, 
we verified the data transfer by visually comparing the written sheet and on-screen 
data. All data were then checked for plausibility by the first author. Free-text answers 
and comments were recorded separately and grouped during the plausibility-process 
by the first author. Missing data were complemented in the database according to the 
annotations if possible. Statistical analysis was performed using SPSS for Windows 
ver. 17.0 (SPSS, Chicago, IL). 
In the descriptive analysis, medians and interquartile ranges (IQR; 25th to 75th 
percentile) were calculated. Pearson’s chi-square test was used to investigate 
possible associations between two variables in a four-fold table. For unrelated group 
analyses, the non-parametric tests Mann-Whitney and Kruskall-Wallis were chosen. 
Analog tests for normal distribution (Student’s t test, analysis of variance (ANOVA)) 
were employed if the results differed. Statistical significance was set at p≤ 0.05.  
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Results 
 
Of the 402 people approached by the pharmacy students when they went to a 
community pharmacy with a prescription for LMWH, 223 agreed to participate in the 
study and 144 completed the study (Fig. 1). Drop-outs did not differ from study 
completers in terms of age (p=0.37, Mann-Whitney test), sex (p=0.93, chi-square 
test), previous outpatient s.c. injection therapies (p=0.76, chi-square test), injections 
administered by another person (p=0.06, chi-square test), little instruction (no oral 
instruction in the injection technique or only by the pharmacy; p=0.66, chi-square 
test), the degree of effort required (p=0.56, Mann-Whitney test), discomfort (p=0.91, 
Mann-Whitney test), or fine motor skills (p=0.40, chi-square test). Patient and 
medication characteristics are listed in Table 1. 
Table 2 summarizes patients’ self-reports on application problems, self-management, 
knowledge, non-compliance, and quality of care experienced (including patient 
satisfaction). We defined drug use problems to be relevant when: (1) patients were 
insufficiently informed about the injection site or technique; (2) injections were 
administered by another person; (3) recapping was carried out; (4) difficulties with 
removal of the needle shield existed; (5) there were discrepancies with prescribed 
therapy duration, daily injections, and injection time. At least one of these problems 
was reported in 181 (85.0%) patients. The community pharmacy instructed 10.8% of 
the patients in the injection technique. 
Self-reported non-compliance showed no association with age (p=0.85, Mann-
Whitney test), previous outpatient s.c. injection therapies (p=0.94, chi-square test), 
injections administered by another person (p=0.18, chi-square test), the degree of 
effort required (p=0.53, Mann-Whitney test), little instruction (p=0.23, chi-square test), 
discomfort (p=0.15, Mann-Whitney test), or fine motor skills (p=0.24, chi-square test). 
No significant associations were seen between the estimations of effort required and 
discomfort experienced with the variables first self-injection under the supervision of 
a medical professional (p=0.62 and 0.56, respectively; Mann-Whitney test), little 
instruction (p=0.66 and 0.22, respectively; Mann-Whitney test), injections 
administered by another person (p=0.32 and 0.83, respectively; Mann-Whitney test), 
or the injection sites abdomen versus thigh (p=0.60 and 0.91, respectively; Mann-
Whitney test). Patients with experience gained from previous outpatient s.c. injection 
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therapies had less discomfort and the injections required less effort (p=0.011 and 
0.022, respectively; Mann-Whitney test). Comfort/confidence with the injections and 
the degree of effort required showed a Spearmen’s correlation coefficient of r= –0.5 
(p<0.001).  
Of the 144 patients completing the study, 126 estimated their comfort and effort 
required at the beginning and at the end of treatment (18 patients did not assess 
these parameters at the final interview as the injections were administered by 
another person). At the beginning of the therapy, 75.4% estimated their confidence 
with self-injecting as high (scale levels 8–10), while 32.5% reported that the injection 
required some effort. At the end of treatment, the corresponding values were 81.7% 
and 38.9%, respectively. Comfort and effort required did not change significantly over 
time (p=0.08 and 0.13, respectively; McNemar test). Nine (7.1%) persons stated that 
the injections required effort throughout treatment, resulting in complete non-
compliance in one case. Ten of the 126 patients sometimes had their injections 
administered by another person.   
A comparison of the abdomen and thigh injections sites revealed no significant 
associations between puncture (p=0.14, Mann-Whitney test) or injection (p=0.38, 
Mann-Whitney test) being unpleasant or painful and the side effects hematoma 
(p=0.50, chi-square test), mild injection site irritation (p=0.34, chi-square test), and 
site pain (p=0.24, chi-square test).  
 
When only patients who always or sometimes self-administered the LMWH were 
considered (n=187), significant differences between the level of difficulty encountered 
in removing the needle shield were found between the different brands of syringes 
needle shields (p=0.037, Kruskal-Wallis test). Based on pairwise differences, the 
needle shield of Fragmin was rated as significantly easier to remove than those of 
Clexane and Fraxiparine (p=0.021 and 0.003, respectively; Mann-Whitney test).  
Post-injection needle guards were only found with Fraxiparine and Fraxiforte devices. 
The needle guards of all syringes in the sharps collectors were correctly positioned 
by 22 (32.8%) of the 67 patients injecting Fraxiparine or Fraxiforte (missing data: 
n=5); 24 (35.8%) patients activated the safety device only partly, and 21 (31.3%) 
patients did not use the needle guards at all or not properly (the protective guard is 
only securely locked in place once a clicking sound is heard after sliding it over the 
needle). 
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The sharps collectors of 180 patients contained a total of 3,218 syringes (median 
10.5, IQR 8─26; range 1–100) (Fig. 2). The pre-filled syringes had volumes of 0.2–
1.0 ml and distances between the plunger and the end of the syringe barrel of 17.0–
38.4 mm (including the air bubble). An overall mean residual drug volume ≥10.0% 
was detected for seven (3.9%) patients (median injection volume 0.6 ml). The highest 
overall mean residual drug volume was 17.9%, and was recorded for a patient who 
had injected 13 syringes of 0.8 ml. 
When only those syringes with residual amounts of LMWH were considered, a 
median of 11.2% (IQR 8.6─17.6%) of the liquid remained in the syringe. In other 
words, if their syringes were not empty, 58 (59.8%) of the 97 persons affected had 
≥10.0% of the total volume not injected (Fig. 3). Comparisons between these 58 
patients and the remaining 122 participants showed no differences in age (p=0.61, 
Mann-Whitney test), sex (p=0.72, chi-square test), fine motor skills (p=0.53, chi-
square test), previous outpatient s.c. injection therapies (p=0.74, chi-square test), 
injections administered by another person (p=0.48, chi-square test), injection 
volumes (p=0.53, Mann-Whitney test), the different brands (p=0.09, chi-square test), 
or number of used syringes as an indication of therapy duration (p=0.14, Mann-
Whitney test). However, the 58 patients injected significantly less into the abdomen 
(p=0.021, chi-square test) and significantly more into the thigh (p=0.019, chi-square 
test; odds ratio 2.16, (95% confidence interval (CI) 1.04–4.51)). 
 
Optional free-text comments provided deeper insights into the nature of the drug use 
problems. Handling difficulties were reported by 33 patients (15.5%); the most 
important of these are listed in Table 3.  
A student observed that the majority of his pharmacy customers’ complaints were at 
the beginning of treatment. In contrast, one patient’s concerns increased towards the 
end of a 4-week treatment. Another person would have even changed from self-
management to injections by another person if the therapy duration was longer than 
the actual 6 weeks. One patient injecting into the thigh had more side effects when 
injecting 0.6 than 0.4 ml.  
Two patients showed restraint in injecting into the thigh; one chose the abdomen 
instead, and the second asked another person to administer the injection. One 
person noticed that hematoma generally developed more often when injecting into 
the abdomen. 
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The support offered was not always satisfying and highlights possible areas for 
improvement in patient care (Table 4). 
 
Discussion 
 
With respect to outpatient s.c. therapies, drug use problems appear to be very 
prevalent, diverse, and complex. They may be associated with the injection itself or 
with the handling of the injection-device. Notably, among the participants in our 
study, 85.0% experienced at least one relevant problem, with recapping being the 
most frequent difficulty encountered: 73.7% of the patients replaced the needle 
shields after injection, which is against recommended practice. At the end of the 
therapy, almost 40% reported that the injection required some effort, and 17.1% 
admitted non-compliance. Medical professionals are unable to ascertain potential 
patient problems in using medication at first glance. As a result, any outpatient s.c. 
therapy poses a challenge not only for the patients themselves and their 
family/friends, but also for health professionals. Therefore, adequate patient care and 
education are crucial and should be optimized.  
 
In our study, 15.5% of patients had their injections performed by another person 
(75.8% of these by family members or friends); of these, 51.5% of patients reported 
that this was due to needle phobia or a fear of puncturing the skin. A review of the 
literature shows a 13–37% non-self-injecting rate [83, 103-105], and in 46.9–66.0% 
of these cases family members administered the injections [103, 105]; 75.0% of 
those who refuse to self-inject report that it is due to fear [103]. This fact should be 
considered when designing patient education programs. If injections are given by a 
family member, this person should be properly instructed. Consequently, physicians, 
hospitals, and community pharmacies should always be equipped with the latest 
leaflets.  
There were no associations between patient characteristics and outcome measures 
with effort required or discomfort, with the exception of previous experience in self-
injecting. A possible explanation for the absence of associations could be the 
heterogeneity of the study sample. Discomfort and effort required did not change 
notably over time. The level of comfort with the procedure was quite high in general, 
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with one reason probably being the fact that 41.8% of the patients already had 
experience of outpatient s.c. injection therapies (this patient group was significantly 
more confident and felt less effort was needed).  
 
Important differences concerning difficulties with the removal of the needle shield 
between different LMWH brands were observed, which confirms the results of a 
previous investigation [106]. Only one third of patients injecting Fraxiparine or 
Fraxiforte applied the needle guards of all their used syringes accurately, and one 
third did not use them at all or used them improperly. Ironically, the danger for needle 
stick injuries increases when the needle guard is positioned but not locked in 
position, as protection is assumed but not provided. There is certainly room for 
improvement in this area through better patient information and education, 
particularly as correctly fitting the guard requires considerable force and coordination 
and the mechanism is poorly marked. Clexane and Arixtra have pre-filled syringes 
equipped with new automatic safety devices; the protective shield is triggered when 
the syringe is empty. In addition to preventing needle stick injuries, the Clexane and 
Arixtra syringes ensure that the whole amount is injected. In our study, there were no 
patients prescribed with Arixtra, and the new Clexane device and the new Fragmin 
Needle-Trap were not yet on the market in Switzerland. 
 
Whether additional drug use problems were also mentioned by the participant when 
he/she was answering the questions posed during the telephone interview depended 
on the participant’s openness for further conversation. It can be assumed that these 
anecdotic application problems would have been noted more frequently if they were 
asked for systematically. An example is the single statement of one participant about 
having more side effects when injecting 0.6 than 0.4 ml into the thigh, which confirms 
the results from another study [107]. Thus, it is likely that not all problems were 
revealed, and those that were may be more multifaceted than previously imagined. 
Prescriptions were often incomplete with regards to therapy duration (27.7%), 
number of daily injections (12.7%), and injection time (73.7%). Missing written 
information makes patient care demanding. The probably unintentional single under- 
or overdoses due to a shift in the time interval of 10–12 h in comparison to the 
prescribed injection time occurred at a sensitive and susceptible moment after 
hospital discharge or at the beginning of treatment in the ambulatory setting. It can 
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be expected that this was a much more common occurrence than the five observed 
cases, as the injection time was not given by 73.7% of patients. As such time-shifts 
generally happen unknowingly, patients would not have mentioned it when assessing 
their own compliance.  
Concomitant self-medication with non-steroidal analgesics did not seem to play an 
important role, although only 25.8% of the participants knew about potential drug 
interactions with LMWH. The participants also showed a lack of knowledge of 
potential side effects. Overall, the assistance provided was appreciated by patients, 
but the amount of help needs to be increased.  
 
Two thirds of the patients injected into the thigh and one third into the abdomen. 
Associations with local side effects or the puncture hole and injection being painful 
were not significant. In additional free-text answers, however, a number of patients 
mentioned problems comparing the two injection sites. The literature also seems to 
be ambiguous on this point: a Brazilian study reported that hematomas were 
observed in 83.7% of patients and that the incidence of hematomas was higher if the 
LMWH injections were administered into the thigh [108]. In contrast, in a special 
series of patients following standard herniotomia, hematoma appeared in 25% of the 
cases when the patients injected into the abdomen and in 9% when they injected into 
the thigh [93]. Other investigations comparing local side effects of LMWH according 
to the two injection sites were not found. In a study with s.c. injections of enfuvirtide, 
injection site reactions were common but mild, and their incidence was higher with 
injections into the abdomen than into the thigh or arm [109]. Patients using a 
sumatriptan self-injector experienced more bleeding and local pain when injecting 
into the thigh compared to the gluteal area; only 15% preferred the thigh as injection 
site [110]. 
 
Every sixth person (17.1%) admitted to having skipped injections. In similar studies, 
non-compliance rates of 4.5–28.3% with different definitions of non-compliance were 
found [83, 103-105]. The main reason in the study of Spahn was forgetfulness 
(94.1%), while 13.1% of the patients discontinued early; all patients younger than 20 
years were classified as unreliable and compliance was dependent on whether 
injections were self-administered [103]. Our study showed a wider variety of reasons 
for non-compliance, with the most important being forgetfulness (44.0%) and early 
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discontinuation (24.0%). We were unable to identify possible risk factors for self-
reported non-compliance, possibly because only 25 patients actually admitted having 
skipped injections, or the diverse reasons for non-compliance. 
Our original objective of determining patients’ taking compliance by comparing the 
number of used syringes with the prescribed therapy duration turned out to be 
impossible. In 36.2% of the final interviews, the date of the last injection was not 
provided, and in 27.7% and 12.7% of the prescriptions, respectively, therapy duration 
and application frequency were not specified. In addition, terms such as “treatment 
until complete mobilization/international normalized ratio twice in therapeutic 
range/next visit with physician” did not enable the date of the last injection to be 
estimated reliably. Furthermore, the prescription date did not necessarily correlate 
with the day of discharge or start of LMWH treatment. Similarly, a patient could be 
fully compliant despite a delay in filling the prescription as─particularly on weekends 
or public holidays─syringes are often dispensed by hospitals or physicians to ensure 
therapeutic coverage. For various reasons, all used syringes were not discarded into 
the sharps collector: delayed delivery of sharps collector, injection with physician 
during consultation, not being at home, flights, holidays, and delivery of syringes by 
the hospital or physician.  
The determination of the residual drug volumes enabled us to partially objectify 
patients’ compliance: residual drug volumes were found rather sporadically, and 
almost half of the patients had no residual drug in any syringe. The overall mean 
residual drug volume was low and negligible, but the total injection volume seemed to 
have an influence, possibly as a result of rising tissue resistance due to the injection 
of higher volumes. This has a particular impact when LMWH are used for the 
treatment of thromboembolisms as higher volumes are administered and patients are 
at greater risk. If residual drug was present, however, it tended to be of 
pharmacological relevance. It can be expected that some of these injections were 
stopped early on purpose. 
Patients injecting into the thigh showed a higher risk of leaving residual volumes, 
which may be due to the smaller area of s.c. tissue in the thigh compared to the 
abdomen. We therefore recommend that patients injecting high volumes or injecting 
into the thigh be advised to monitor closely whether the syringe is empty and be 
aware that they might need more force towards the end of the injection. Other risk 
factors for residual volumes could not be identified. Sufficient evidence was not 
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collected on this aspect, probably because the therapy durations were mostly short, 
with a median of 10.5 syringes in the sharps collectors. It has also to be taken into 
account that almost half of the patients (47.2%) had to inject only small volumes of 
≤0.3 ml, and a minority of 9.4% injected volumes of ≥0.7 ml.  
 
The strength of our study is the heterogeneous study population, covering a broad 
spectrum of drug use problems and reflecting daily life activities. Not only 
comparatively healthy patients participated in our study (e.g., those with a foot injury, 
long-distance travelers), but also seriously ill persons, such as patients with 
pulmonary embolism, lung transplantations, or paraplegia. However, categorization 
of such a study population is difficult. The community pharmacies were distributed 
more or less throughout Switzerland, which ensured that possible regional 
differences in the quality of care on the part of the physicians, hospitals, and 
community pharmacies were taken into account. 
The main limitations of our study are the data collection by 95 students, a consent 
rate of only 55.5%, and a possible bias due to patient selection. Polymorbid or 
cumbersome pharmacy customers were less likely asked to take part in the study, 
whereas regular or pleasant customers were more often invited to participate. 
Furthermore, interested and motivated patients are more likely to participate in a 
study and to be more compliant, reflecting daily life in a much too positive way. 
Another weakness is the dropout rate of 32.4% at the final interview, setting 
constraints on the conclusions that could be drawn on self-reported non-compliance 
and the estimations of comfort or effort required in the course of the therapy duration. 
As no prescription duplicate was requested and data collection was anonymous, no 
retracing or access to medical history was possible. Therefore, the results are based 
on patients’ self-reports only. Our determination of the residual drug volume by 
measuring the distance between plunger and the end of the cylindrical body was the 
most reliable measurement, but the approach has limitations: as the liquid had often 
evaporated, we were unable to recognize whether we were measuring only missing 
liquid or the missing liquid together with the air bubble. Thus, the results are only 
estimations, although they are helpful in providing an impression of the magnitude of 
the problem. Hence, the true mean residual drug volumes may even be smaller. 
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Conclusion 
 
Low-molecular-weight heparins represent a good model for studying outpatient s.c. 
therapies in primary care. Among our patient cohort, 85.0% reported some relevant 
drug use problem, whereas no clear factors were associated with non-compliance, 
the injection site (beside residual drug), and discomfort or effort required (beside prior 
injection use). Around 4% of patients had a considerable mean residual drug volume 
(≥10.0%) in their syringes, with a higher risk of leaving medication when injection was 
into the thigh. The challenge facing not only for pharmacists but all health 
professionals as well as the pharmaceutical industry (design of injection-device and 
instruction leaflets) is to successfully contribute to a successful therapy. From a 
patient’s point of view, injections require some effort. Therefore, it can be imagined 
that injection-free therapies for patients on chronic antithrombotic therapy would be 
appreciated. 
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Tables and figures 
 
Table 1 Characteristics of study sample (ntotal=213)  
Patient and clinical characteristics n (%)a Missing 
data  
n (%) 
Patient characteristics 
Age (years) 
Males 
Education  
 Mandatory school 
 Skilled worker 
 Technical college + university 
Previous outpatient s.c. injection therapies  
Impairment in daily living due to arm, shoulder, or hand 
Arthritis in arm, shoulder, or hand 
Impaired vision (using glasses or contact lenses) 
54 (39–70) 
108 (50.7) 
 
24 (11.3) 
123 (57.7) 
52 (24.4) 
89 (41.8) 
29 (13.6) 
32 (15.0) 
27 (12.7) 
2 (0.9) 
2 (0.9) 
14 (6.6) 
 
 
 
1 (0.5) 
9 (4.2) 
20 (9.4) 
26 (12.2) 
Medication characteristics 
Medication 
 Fragmin (dalteparin) 
 Fraxiparine (nadroparin) 
 Clexane (enoxaparin) 
 Fraxiforte (nadroparin) 
 Sandoparin (certoparin) 
Application once daily 
 Not specified on prescription 
Concomitant medication with an increased bleeding risk 
(not necessarily on the same prescription) 
 Anticoagulant (acetylsalicylic acid,  
phenprocoumon, acenocoumarol, clopidogrel) 
- anticoagulant stopped during LMWH treatment 
 Prescribed analgesic 
- only paracetamol 
 Self-medication with analgesics 
- only paracetamol 
Reason for LMWH treatment (multiple answers possible)  
 
99 (46.5) 
63 (29.6) 
33 (15.5) 
9 (4.2) 
9 (4.2) 
171 (80.3) 
27 (12.7) 
 
 
68 (31.9) 
 
28/68 (41.2) 
146 (68.5) 
37/146 (25.3) 
20 (9.4) 
9/20 (45.0) 
 
0 (0.0) 
 
 
 
 
 
1 (0.5) 
 
 
 
4 (1.9) 
 
3/68 (4.4) 
7 (3.3) 
0/146 (0.0) 
2 (0.9) 
0/20 (0.0) 
0 (0.0) 
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 Surgery/injury of 
- lower limb 
- hip 
- upper limb 
 Thrombosis, embolism 
 Perioperative management/bridging 
 Atrial fibrillation, myocardial infarction 
 Cancer 
 Pregnancy, hormone therapy 
 Abdominal surgery 
 Long-distance travel 
 Other 
 
112 (52.6) 
11 (5.2) 
7 (3.3) 
35 (16.4) 
16 (7.5) 
8 (3.8) 
7 (3.3) 
6 (2.8) 
6 (2.8) 
4 (1.9) 
12 (5.6) 
a All data is presented as the number (n) with the percentage in parenthesis with the 
exception of ‘Age‘, which is presented as the median with the interquartile range in 
parenthesis. 
s.c. Subcutaneous; LMWH Low-molecular-weight heparins 
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Table 2 Self-reported quality of care (including patient satisfaction), self-
management, drug use problems, knowledge, and non-compliance (ntotal=213) 
Parameters on patients’ self-reports n (%)a Missing data  
n (%) 
Quality of care and patient satisfaction 
Oral instruction in injection technique (previous and present 
treatment)  
 None  
 Only by the pharmacy 
Insufficiently informed about injection site 
Insufficiently informed about injection technique 
Alcohol swab provided 
First self-injection in the presence of a medical professional  
 Provided 
- helpful 
 Not provided, but desired 
Delivery of leaflet 
 Provided 
- helpful 
 Not provided, but desired 
First injection administered by the pharmacist 
 Provided 
 Not provided, but desired 
All injections administered by the pharmacist 
 Provided 
 Not provided, but desired 
Delivery of sharps collector 
 Provided 
- helpful 
 Not provided, but desired 
Injection training into a “phantom” (injection pillow) 
 Provided 
- helpful 
 Not provided, but desired 
Video tape 
 Provided 
 
 
10 (4.7) 
8 (3.8) 
8 (3.8) 
14 (6.6) 
200 (93.9) 
 
111 (52.1) 
97/111 (87.4) 
15/102 (14.7) 
 
41 (19.2) 
33/41 (80.5) 
28/164 (17.1) 
 
0 (0.0) 
9/200 (4.5) 
 
0 (0.0) 
8/201 (4.0) 
 
203 (95.3) 
135/203 (66.5) 
0/10 (0.0) 
 
7 (3.3) 
6/7 (85.7) 
10/198 (5.1) 
 
1 (0.5) 
0 (0.0) 
 
 
 
7 (3.3) 
9 (4.2) 
1 (0.5) 
 
0 (0.0) 
12/111 (10.8) 
17/102 (16.7) 
 
8 (3.8) 
3/41 (7.3) 
22/164 (13.4) 
 
13 (6.1) 
42/200 (21.0) 
 
12 (5.6) 
33/201 (16.4) 
 
0 (0.0) 
38/203 (18.7) 
4/10 (40.0) 
 
8 (3.8) 
1/7 (14.3) 
33/198 (16.7) 
 
10 (4.7) 
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- helpful 
 Not provided, but desired 
0/1 (0.0) 
13/202 (6.4) 
0/1 (0.0) 
33/202 (16.3) 
Self-management (multiple answers possible) 
Injection site 
 Thigh 
 Abdomen 
 Back of the upper arm 
 Other 
Injections administered by another person (sometimes or 
always) 
 by family member/friend 
 by medical professional 
Reasons for not self-injecting 
 needle phobia 
 fear of puncturing skin 
 severely disabled 
 family member is a medical professional 
 other 
Illegitimate recapping 
  
146 (68.5) 
80 (37.6) 
2 (0.9) 
2 (0.9) 
33 (15.5) 
 
25/33 (75.8) 
9/33 (27.3) 
 
9/33 (27.3) 
8/33 (24.2) 
4/33 (12.1) 
3/33 (9.1) 
8/33 (24.2) 
157 (73.7) 
0 (0.0) 
 
 
 
 
0 (0.0) 
 
 
 
5/33 (15.2) 
 
 
 
 
 
5 (2.3) 
Application problems 
Difficulties with removal of needle shield 
Puncture is unpleasant/painful  
Injection is unpleasant/painful 
Degree of effort required to inject (scale: 1–4)  
Confidence/lack of discomfort (scale: 0–10)  
Side effects (multiple answers possible) 
 Hematoma at injection site 
 Mild injection site irritation/burning 
 Hematoma in general 
 Site pain 
 Exanthema 
 Bleeding tendency 
 Induration  
 Epistaxis 
 Other 
→ no action taken by study participants 
28 (13.1) 
105 (49.3) 
113 (53.1) 
2 (1-3)  
9 (7-10) 
105 (49.3) 
79 (37.1) 
36 (16.9) 
16 (7.5) 
15 (7.0) 
4 (1.9) 
4 (1.9) 
4 (1.9) 
2 (0.9) 
9 (4.2) 
77/105 (73.3) 
1 (0.5) 
3 (1.4) 
6 (2.8) 
5 (2.3) 
26 (12.2) 
2 (0.9) 
 
 
 
 
 
 
 
 
 
13/105 (12.4) 
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→ met criteria for reporting an adverse event to regulatory  
authority 
1 (0.5) (arm 
exanthema) 
0 (0.0) 
Knowledge 
Discrepancy with prescribed therapy duration 
 Not specified on prescription 
Discrepancy with prescribed daily injections 
  Not specified on prescription 
Discrepancy with prescribed injection time 
 Not specified on prescription 
Nescience of reason for LMWH treatment 
Nescience of potential interactions with NSAR 
Nescience of potential side effects 
9 (4.2) 
59 (27.7) 
3 (1.4) 
27 (12.7) 
7 (3.3) 
157 (73.7) 
6 (2.8) 
158 (74.2) 
116 (54.5) 
4 (1.9) 
 
3 (1.4) 
 
3 (1.4) 
 
0 (0.0) 
2 (0.9) 
2 (0.9) 
Self-reported non-compliance (assessed at final interview with n=144 patients) 
Difficulties with injecting the LMWH timely 
Applications exceeding +/– 2 h of assigned injection time 
Skipping injections (n=146; completion of database according 
to annotiations) 
 1 time 
 >3 times 
Reason for skipping injections (multiple answers possible) 
 forgotten 
 early discontinuation 
 not being at home 
 otherb 
15 (10.4) 
5 (3.5) 
25 (17.1) 
 
8/25 (32.0) 
5/25 (20.0) 
 
11/25 (44.0) 
6/25 (24.0) 
2/25 (8.0) 
7/25 (28.0) 
2 (1.4) 
1 (0.7) 
0 (0.0) 
 
4/25 (16.0) 
 
1/25 (4.0) 
NSAR Non-steroidal anti-rheumatics 
a All data is presented as the number (n) with the percentage in parenthesis with the 
exceptions of ‘Degree of effort required to inject’ and ‘Confidence/lack of discomfort’, 
which are presented as the median with the interquartile range in parenthesis 
b Injections every 2–3 days depending on appearance of leg pain; vomiting or 
abdominal pain; delayed filling of the prescription; skeptical towards LMWH; news 
coverage about contaminated heparins; injection required too much effort (complete 
non-compliance); dropping a syringe leading to an insufficient number of syringes 
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Table 3 Handling difficulties (multiple statements per person possible) 
Flap of paper backing on blister pack: Too small to remove the syringe from its packaging 
Removal of needle shield: Tricky; difficulties due to single-handed removal; bending the 
needle; total liquid loss due to pulling the plunger rod 
Needle: Too sharp; not sharp; twice blocked; bent 
Air bubble: Uncertainty whether air bubble needs to be removed; annoying; no air bubble 
Injection: Injection more painful with small injection angle (n=2); injection needs lots of force 
(n=2); uncertainty concerning the insertion length of the needle into the skin; coordination 
difficult regarding quick insertion of the needle vs. slow injection; high resistance when 
pushing the plunger rod in the beginning leading to a sudden and quick injection; needle 
accidentally came out of the skin during injection; liquid loss during first injection; early 
discontinuation due to lots of pain and problems during injection; injection by another person, 
because of inability to self-inject into the back of the upper arm; setting back injection time 
every day 15 min from 7 p.m. (injection time in hospital) to 11 p.m. (preferred injection time at 
home) 
Recapping: Needle stick injury; needle easily penetrates the soft needle shield 
Syringe: Syringe in general very small and hence difficult to handle (n=3); uncertainty 
whether total volume was injected (n=3); dropping the syringe before injection (n=2); finger 
flange too small (n=2); difficulties with positioning the needle guard of Fraxiparine 
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Table 4 Room for improvement in quality of care (multiple statements per person 
possible) 
More information: On thromboembolism (n=4) and its prevention (n=2); on LMWH and side 
effects (n=2) 
Improved instruction in the injection technique: Better instruction (n=9); increased patient 
involvement (n=8); instructions not only orally but with demonstration of the injection 
technique (n=2); self-injections during the whole hospital stay and not only on the day before 
hospital discharge (n=2); repetition of the instructions when collecting their prescription 
Consistent instructions: On injection angle (n=3); injection site (n=2); skin fold; air bubble 
Better leaflets: On terminology; font size; foreign languages 
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Fig. 1 Study flowchart with numbers of patients and reasons for dropout 
LMWH Low-molecular-weight heparins 
Handling difficulties and drug use problems with pre-filled syringes 
 72
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Prevalence of syringes with residual drug irrespective of the volume amount 
Handling difficulties and drug use problems with pre-filled syringes 
 73
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Mean proportion of residual drug in used syringes still containing medication. Only those syringes with residual amounts of 
LMWH (97 patients, 304 syringes; range 1–16 syringes) were considered in the analysis 
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3 Outpatient low-molecular-weight heparin therapy 
 
 
 
 
  
Outpatient low-molecular-weight heparin therapy 
 75
Project C:  
Self-management of outpatient low-molecular-weight heparin 
therapy: impact of pharmaceutical care 
 
 
 
 
Seraina Mengiardi1, Dimitrios A. Tsakiris2, Viviane Laufer-Molnar3, Urs Kohlhaas-
Styk3, Michael Mittag1, Stephan Krähenbühl4, Kurt E. Hersberger1 
 
 
 
 
 
 
1 Pharmaceutical Care Research Group, University of Basel, Switzerland 
2 Division of Hematology, University Hospital Basel, Switzerland 
3 Clinic for Orthopedic Surgery and Traumatology, Kantonsspital Bruderholz, 
Switzerland 
4 Division of Clinical Pharmacology and Toxicology, University Hospital Basel, 
Switzerland 
 
 
 
 
 
 
Ann Pharmacother; submitted 
Outpatient low-molecular-weight heparin therapy 
 76
Abstract 
 
Background 
The effectiveness of community-pharmacy-based interventions in preventing 
problems that arise during subcutaneous (s.c.) self-injections of low-molecular-weight 
heparins (LMWH) is unknown.  
 
Objective 
To develop a standard operating procedure (SOP) for community pharmacists and to 
compare pharmaceutical vs. standard care in both clinical and daily life settings. We 
hypothesized that: pharmaceutical care results in improved compliance, safety, and 
satisfaction, and in fewer complications; the interventions used are feasible in daily 
life; and the results achieved in clinical and daily life settings are comparable. 
 
Methods  
In the clinical setting (randomized controlled trial), patients were recruited 
sequentially in hospital wards; in the daily life setting (controlled trial), recruitment 
took place in community pharmacies by trained master students and pharmacists. 
Interventions were offered according to patient needs. Data were collected by means 
of a monitored self-injection at home and structured questionnaire-based telephone 
interviews at the beginning and the end of the LMWH treatment. 
 
Results  
The median age of the 139 patients was 54 years (interquartile range 40−65 years). 
Interventions resulted in improved application quality (p<0.01) and knowledge 
(p=0.03). Oral instructions were pivotal for improving patients’ application quality. We 
found no significant score differences between the intervention groups in the clinical 
and daily life settings. Patients’ baseline skills were high, with the lowest score being 
0.86 (range −2.00 to +2.00). Compliance rate was high (95.8%). 
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Conclusions 
Our SOP for pharmacist interventions was of good quality, adequate, appreciated, 
and feasible in daily life. Patients are capable of managing s.c. injection therapies if 
adequate assistance is provided. 
 
Keywords  
Low-molecular-weight heparin  Outpatients  Subcutaneous injections  Self 
administration  Pharmaceutical care  Community pharmacy 
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Introduction 
 
The number of medications that cannot be applied orally but have to be administered 
subcutaneously (s.c.) is rising; such medications are used to treat a wide range of 
diseases, e.g. thromboembolism, diabetes, multiple sclerosis, arthritis, anemia, 
cancer, female infertility, hepatitis B and C, migraine, osteoporosis, and human 
immunodeficiency virus (HIV). Different devices are used to deliver such medication, 
e.g. pre-filled syringes, pens, injectors, and vials/ampules, where preparation is 
needed before injection. Self-injections in an outpatient setting are encouraged to 
strengthen patient responsibility for his/her own disease management, grant greater 
independence, and reduce costs.  
For prophylaxis and treatment of venous thromboembolisms, the use of low-
molecular-weight heparins (LMWH) is well established [3, 8, 10, 18]. Therapies are 
often inititated during a hospital stay or at discharge, followed by daily s.c. self-
injections for a period of time varying from days to weeks or even longer. Because 
after discharge most patients visit a community pharmacy to fill their prescription, 
pharmacists play an important role in the continuity of care by assuring correct drug 
use over the prescribed time [45, 53]. The community pharmacist’s conventional role 
of preparing and dispensing drugs is changing, and the provision of new 
pharmaceutical services is needed [45]. The influence of pharmaceutical care on 
asthma, elevated lipid levels, hypertension, and diabetes has been investigated [111-
117], but knowledge of the effectiveness of community-pharmacy-based 
interventions on problems in self-administering s.c. injection therapies is lacking.  
Enhancement of compliance is a multilevel challenge that includes a combination of 
different interventions, such as patient education with oral and written instructions, 
monitoring, telephone follow-up, reminder systems, and use of patient-tailored care 
[57, 77]. It has been reported in the literature that problems with self-administering 
outpatient LMWH treatments are prevalent, diverse, and may concern the injection 
itself or handling of the injection device [35, 106, 118]. Previous interventional studies 
recruited 40−214 patients, and concentrated on orthopedic patients from selected 
clinics or hospitals [83, 103-105]. All patients received educational programs that 
included instructions in the injection technique, performing their first self-injection in 
the presence of a medical professional, and, occasionally, written information or a 
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video tape. A search of the literature failed to identify studies that were controlled, 
examined feasibility of the interventions in daily life, or objectively assessed each 
patient’s injection technique in everyday life after hospital discharge (e.g. direct 
observation technique, DOT, during a home visit). 
We therefore designed a 4-arm, partly randomized, parallel, open-label, active 
control, phase 4, supportive care, safety study. Our aims were: (1) to develop a 
standard operating procedure (SOP) for the first instruction in the s.c. injection 
technique given by a community pharmacist and the subsequent pharmaceutical 
care provided during outpatient therapy; and (2) to compare intensive pharmaceutical 
care vs. standard care in both a clinical setting (hospital wards under study 
conditions) and in a daily life setting (community pharmacies following their daily 
routine). We hypothesized that: (1) intensive pharmaceutical care for outpatients self-
injecting LMWH results in improved compliance, safety, and satisfaction, as well as in 
fewer complications; (2) the interventions used are feasible in the everyday routine of 
community pharmacies; and (3) the results achieved in clinical and daily life settings 
are comparable. 
 
Methods 
 
Setting and study population 
 
This study comprised both clinical and daily life settings. The clinical setting arm 
(ClinS) was a randomized controlled trial (RCT). Patients were recruited sequentially 
into the intervention (ClinS-I) or control (ClinS-C) groups by the primary investigator 
from two orthopedic clinics (Kantonsspital Bruderholz, University Hospital Basel), 
from an orthopedic early rehabilitation ward of the University Hospital Basel (Felix 
Platter-Spital), and from an emergency department (University Hospital Basel) 
between June 2007 and June 2009. The primary investigator had attended a certified 
course for parenteral injection techniques and four specialized courses on the s.c. 
injection technique, including clinical training by nursing staff. 
The daily life setting arm (DailyS) was a controlled trial. Patients were recruited 
sequentially in community pharmacies: for the control group (DailyS-C) by 65 trained 
students from the University of Basel during their internship between January and 
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May 2008 [35] and for the intervention group (DailyS-I) by trained community 
pharmacists between March 2008 and June 2009. We invited all 87 community 
pharmacies in the region to attend one of our courses, which included background 
information on thromboembolic diseases and heparin therapy, case analysis of 
LMWH prescriptions, and instructions in the s.c. injection technique, which included 
clinical training, presentation of the DailyS, and distribution of study material. Out of 
the course participants, 21 community pharmacies agreed to recruit patients for the 
DailyS-I arm. 
We defined the following inclusion criteria: patients aged ≥18 years with a 
prescription for an outpatient LMWH treatment with pre-filled syringes; Fragmin 
(dalteparin, Pfizer AG; ClinS) or all brands of LMWH (DailyS); self-injection; 
prophylactic or therapeutic use; first or previous outpatient s.c. treatment; all therapy 
durations; no comprehension difficulties due to language. 
 
Interventions 
 
Our SOP comprised the following interventions, which were offered and applied 
according to patient need (ClinS-I, DailyS-I): delivery of a leaflet, including oral 
instruction; delivery of a manual for s.c. injection; delivery of a kit containing 20 
alcohol swabs, cotton swabs, and plasters each; oral instruction in s.c. injection 
technique; injection training into a ‘phantom’ (injection pillow; PharmaDesign Inc., 
Warren, NJ, USA; delivered by Pfizer AG); instruction in the injection technique using 
a commercial video (CD-ROM or website); (first) self-injection in the presence of a 
pharmacist, or (first) injection administered by a pharmacist (ClinS: primary 
investigator; DailyS: trained community pharmacist). 
The leaflet (4 pages) and the laminated manual (1 page) were created and revised 
regularly by reviewing package inserts, current commercial leaflets, and kits for 
LMWH or other medications s.c. administered, as well as patient-tailored websites of 
pharmaceutical companies. The leaflet contained detailed background information 
about: reasons for the LMWH treatment; effects, indications, injection times, therapy 
durations, daily injections, and potential adverse drug reactions of LMWH, as well as 
potential interactions with OTC medications; actions to be taken if a dose was 
skipped; and thrombosis and embolism, including their symptoms and actions to be 
taken. A step-by-step instruction in the s.c. injection technique with illustrations and 
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explanations completed the leaflet, along with a diary to record daily injections for 
self-monitoring. The manual was designed to be a quick reference card providing a 
brief summary of the sequential steps of the s.c. injection. Both the leaflet and 
manual were reviewed by a hematologist. 
 
Data collection 
 
In the clinical setting arm (RCT), patients received standard hospital care. Patient 
recruitment was performed by the primary investigator by regularly contacting the 
nurses or physicians to ask for potential study participants. The hospital staff were 
not involved any further in the study. If the patient met the inclusion criteria and 
written informed consent was obtained, a sharps collector (E-safe) for the used 
syringes and written patient information was delivered. The 1:1 randomisation was 
performed by using a research randomizer for random sampling and random 
assignment [119], and patients were sequentially assigned to the intervention or 
control group. Interventions were offered and applied according to patient need 
(ClinS-I), either at the patient’s bedside or immediately after discharge in the 
‘Emergency Pharmacy Basel’ – an emergency community pharmacy open only at 
night, weekends, and holidays – which was used as study centre during the day. 
Patients of the control group (ClinS-C) received standard care by filling their 
prescription in the community pharmacy of their choice. 
 
In the daily life setting arm, routine prescription validation was performed by each 
community pharmacy (standard care) when a LMWH was requested. If the patient 
met the inclusion criteria and oral (DailyS-C) or written (DailyS-I) informed consent 
was obtained, the trained community pharmacists (DailyS-I) offered and applied the 
interventions according to each patient’s needs and informed the primary 
investigator. All patients received at least a sharps collector (E-safe) for the used 
syringes and written patient information. To get their feedback and keep motivation 
high, the primary investigator contacted the intervention community pharmacies 
(DailyS-I) regularly by phone. 
 
Data collection was identical with a former study (structured questionnaire-based 
interviews at the beginning and after completion of the s.c. therapy; analysis of used 
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syringes) [35]. At the end of the study, the final interview was performed either at the 
community pharmacy, when sharps collectors were returned (DailyS-C) or by phone 
call (ClinS; DailyS-I), and patients were asked to return their sharps collectors by 
mail. At a pre-arranged date and at her/his individual injection time, each patient was 
monitored during self-administering an s.c. injection and rated using a developed 
DOT-based data collection sheet. Immediately after the DOT, the injection technique 
was reviewed with the patient. During the DOT, the investigator would only have 
intervened with serious handling errors, which never was the case. Data collection 
was performed by the primary investigator in the ClinS and DailyS-I arm. The DailyS-
C arm consisted of a subpopulation of a former study [35]: to get this subpopulation, 
each trained master student had to recruit one patient for whom they performed the 
interviews and the DOT. 
The data collection was anonymized by assigning a code to each patient. The study 
protocol was approved by the local Ethics Committee of Basel (EKBB 95/07; 
ClinicalTrials.gov identifier: NCT00794560). 
 
Outcome measures 
 
To assess each patient’s skills, we assigned points to every answer (+2=correct 
answer; +1; 0; -1; –2=wrong answer). For each question, we awarded at most +2 and 
−2 points. To minimize bias generation with the complex data transformation, we 
completed missing data by the mean values. A committee consisting of a 
hematologist, a physician working as a medical advisor for Fragmin, a nurse, two 
clinical pharmacists, the primary investigator, and the master student rated the 
importance of the questions by using a 4-point scale. Cronbach’s alpha reliability 
coefficient (α) was used as a measure of the internal consistency and reliability of the 
scores (range: 0−1). The mean values on the 4-point scales (range: 1.6−3.9; α = 
0.80) were converted into a weighting range between 1.0 and 2.0. This means that a 
question rated to be very important received twice as much emphasis as one rated to 
be of average importance. The scales were then computed as weighted means of the 
individual items (i.e. score minimum = −2.00; score maximum = +2.00). We defined 
different domains to group the questions and to facilitate comparisons (Table 1). The 
catalogue with the questions assigned to the particular domains is listed as 
supplementary data (Appendix Table 1). 
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By comparing the number of used syringes with the prescribed therapy duration, we 
determined levels of patient ‘taking’ compliance (= syringe count: missing syringes 
are used as a measure for non-compliance). If the therapy duration was not specified 
on the prescription or unclear (terms such as ‘treatment until complete mobilization, 
INR twice in therapeutic range, next visit with physician’), we referred to the dates of 
the first and last injections. If these dates and the therapy duration were not provided, 
if there was an unscheduled visit with the physician/hospital, or if the sharps 
collectors were missing, we were unable to determine the compliance reliably and 
classified the patient’s compliance as ‘not determinable’. Patients who discontinued 
their s.c. treatment early due to full physical load were classified as fully compliant. If 
sharps collectors were not returned, patients were reminded by mail, e-mail, phone 
call, or text message. An internal analysis showed smaller overall mean residual drug 
volumes in the used syringes compared to a former study, where they were 
interpreted as low and negligible [35]. Thus, we did not take this parameter into 
further consideration. 
 
Validation 
 
The purposes of the validation were to screen the questionnaire for its 
comprehensibility and completeness, to standardize the questionnaire- and DOT-
based data collection, as well as to check the primary investigator’s and the data-
collecting students’ consistency. 
Thirty-four pharmacy students serving their internship in 2007 were asked to fill in the 
questionnaire by answering the questions appropriate for healthy subjects. In 
addition, as a pilot, the full questionnaire-based interviews were performed with 4 
people, during which both the primary investigator and a master student filled in the 
questionnaire. Discrepancies with recording were discussed and ruled out. To 
validate the DOT, the primary investigator and the master student observed the same 
34 pharmacy students self-administering a s.c. injection (0.2 ml, 0.9% sodium 
chloride). Two months previously, the students had received instructions in the s.c. 
injection technique, including clinical training. In the same manner as described 
above, divergencies (of at most 20%) were identified and resolved.  
To validate the monitoring and recording skills of the students recruiting for the 
control group of the DailyS, they were asked to analyze three videos using the DOT-
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based data collection sheet. On each video, the primary investigator self-
administered an s.c. injection (0.2 ml, 0.9% sodium chloride) with purposeful errors 
reflecting daily life situations. After recording, each video was discussed with the 
students. The students’ accuracy improved from video 1 (mean value: 71.4%; 
minimum: 55.0%) to video 2 (75.2%; 60.0%) to video 3 (88.1%; 71.7%). 
 
Statistical analysis 
 
Data sheet processing, plausibility testing, and statistical analysis were performed in 
the same manner as described in a former study [35]. Because the statistical 
procedures used were either very straightforward, such as comparison of two sample 
means, or included parameters that were impossible to estimate with any confidence, 
such as the variance of questionnaire scores, we did not compute a power analysis. 
For a comparison of sample means, we have 32−40 subjects per group, so we can 
expect to find differences in the region of one half to one third of a standard 
deviation. For our aim, which is to find differences that are relevant in daily life, we 
believe that this is sufficient. For more complex analyses, statistical power may vary, 
and will typically be somewhat higher, because the more complex statistical models 
are better at reducing error variation. Also, we use nonparametric comparisons if 
possible, which are generally more stable, at a potential cost of statistical power. As 
a rule of thumb, statistical power of parametric tests is roughly 5% higher if data 
follow an exact normal distribution, but can quickly deteriorate if normal distribution is 
violated (even if the violation is mild). Note that for the domains, we cite the 
arithmetic mean and not the median, because the median does not offer a precise 
estimate for scales with few levels. The median almost always takes the value of a 
scale level, so if the scale has three levels, the median can take only three different 
values. Because of the way we computed our scores, different scores have a 
different number of levels, rendering a comparison of score medians very difficult to 
interpret. 
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Results 
 
Of the 484 persons assessed for eligibility, 154 were included into the study and the 
data of 139 patients were analyzed (Fig. 1). Ten patients (16.7%) out of 60 not 
meeting the inclusion criteria in the ClinS arm reported needle phobia. Fourteen 
community pharmacies recruited 1−7 patients, 7 community pharmacies could not 
recruit any patients. Patient and medication characteristics and parameters on 
patients’ self-reports are summarized in Table 2. Patients of the ClinS arm were more 
experienced in self-injecting than patients of the DailyS arm (p=0.04, chi-square test). 
Previous outpatient s.c. injection therapies had no influence on the scores (p=0.16 to 
p=0.90, Mann-Whitney tests), but led to a decrease in subjective effort required to 
administer the injection (p=0.02, Mann-Whitney test) and to an increase in 
confidence (p=0.04, Mann-Whitney test). In the DailyS arm, patients of the control 
group mentioned less adverse drug reactions than patients of the intervention group 
(p<0.01, chi-square test). This was confirmed by comparing the combined control 
(ClinS-C + DailyS-C) and intervention (ClinS-I + DailyS-I) groups (p<0.01, chi-square 
test). Other patient characteristics and parameters on patient’s self-reports were 
comparable within the ClinS arm (ClinS-I vs. ClinS-C), within the DailyS arm (DailyS-I 
vs. DailyS-C), between the ClinS (ClinS-I + ClinS-C) and the DailyS (DailyS-I + 
DailyS-C), between the assembled intervention (ClinS-I + DailyS-I) and control 
(ClinS-C + DailyS-C) groups, and within the two intervention groups (ClinS-I vs. 
DailyS-I). No study participant had a thromboembolic event during the observation 
period (i.e. until the end of the individual LMWH treatment). 
 
Table 3 shows the scores of the patients in the different study arms, as well as for the 
combined intervention (ClinS-I + DailyS-I) and control (ClinS-C + DailyS-C) groups. 
There was no strong correlation between the domains (Spearman’s correlation 
coefficient of r=−0.02 to 0.2) with significance only for knowledge and application 
quality (DOT) (r=0.2, p=0.01). A direct correlation between ‘Reality’ (objectively 
assessed by investigators, Table 1) and ‘Self-assessment’ (subjectively assessed by 
patients themselves) was only possible for the application quality; it resulted in a low 
and non-significant Spearman’s correlation coefficient value of r=−0.1 (p=0.20). 
There were no significant differences between the intervention groups of the ClinS 
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and DailyS (p>0.57, except for estimated assistance quality: p=0.14, Mann-Whitney 
test). 
The application quality (DOT) was not influenced by age (r=−0.1, p=0.15), sex 
(p=0.63, Mann-Whitney test), previous outpatient s.c. injection therapies (p=0.22, 
Mann-Whitney test), first  self-injection in the presence of a medical professional 
(p=0.38, Mann-Whitney test), fine motor skills (p=0.91, Mann-Whitney test), or the 
injection site (p=0.06, Mann-Whitney test; a trend towards a higher score with 
injections into the thigh (mean 1.17; standard deviation 0.34) than into the abdomen 
(mean 1.03; standard deviation 0.39) was observed). The DOT was performed 120 
times at patients’ homes, 3 times at the study centre, 2 times at their workplace, and 
3 patients recorded their injection for DOT on a video. The observation of a self-
injection was either helpful and increased confidence (n=5) or made the patient 
insecure and nervous (n=5). We were unable to perform 11 DOTs (7.9%) as: 
patients’ individual therapy durations were very short and the treatment had already 
been terminated due to an INR in therapeutic range (n=2) or full physical load (n=2); 
the patient’s home was too far away from study centre (n=3), it was impossible to find 
an appropriate date (n=2), or the patient refused the DOT (n=2).  
The sharps collectors of 128 patients contained a total of 3,137 syringes (median: 18, 
interquartile range: 10–39.5; range: 2−93). Eleven sharps collectors were missing: 
Four patients lived abroad and the sharps collectors probably didn’t cross the border, 
one person didn’t want a sharps collector, and in the remaining 6 cases, the reason 
is unknown. In 41.0%, the therapy duration was not specified or unclear. Results of 
the syringe count are listed in Table 3. The compliance of 24 (17.3%) patients was 
not determinable; 12.9% of patients admitted skipping injections, whereas the 
objective syringe count detected non-compliance with 37.4% of patients (p<0.01, chi-
square test). A greater than 2-hour delay to the prescribed injection time was 
mentioned by 15.8% patients (4.3% missing), leading to a correct ‘taking’ compliance 
(syringe count), but to a non-compliance in terms of timing; there was no difference 
between the combined control (ClinS-C + DailyS-C) and intervention (ClinS-I + 
DailyS-I) groups (p=0.17, chi-square test). 
 
Table 4 shows the error rates of clinically relevant administration steps and the 
influence of the interventions upon them. We found no associations between burning 
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and not waiting for the alcohol to evaporate (p=0.34, chi-square test) or skin area 
being swabbed after injection with the alcohol swab (p=0.13, chi-square test). 
Patients made use of the following compliance aids: integration of the self-injection 
into a daily routine (n=13), setting an alarm (n=5), and using a diary (n=3). Handling 
difficulties concerned the high forces needed when pushing the plunger rod in the 
beginning leading to a sudden and quick injection (n=4), as well as the small size of 
the finger flange (n=4), the thumb grip, and the syringe in general. Seven patients 
stated that they required much more effort in earlier LMWH treatments. 
 
According to our SOP, the objective assistance quality in the two study arms ClinS-I 
and DailyS-I was patient-tailored as interventions were offered and provided only if 
required (Table 5). No additional care was desired. Analyzing the free-text comments 
of patients rating the interventions as not helpful, we worked out that these patients 
declared having no need of them (leaflet p<0.01; manual p<0.01; oral instructions 
p<0.01; injection training into a ’phantom’ p=0.01, chi-square tests). Patients of the 
ClinS-I received more oral instructions (93.9% vs. 70.0%; p=0.02, chi-square test) 
and injection training into a ’phantom’ (84.8% vs. 22.5%; p<0.01, chi-square test). On 
the other hand, patients of the DailyS-I assessed the leaflet to be more helpful 
(53.1% vs. 80.6%; p=0.02, chi-square test). Patients who received oral instructions 
reached higher scores in the application quality (DOT) (p=0.04, Mann-Whitney test) 
and self-assessed their application quality more sceptically (p=0.01, Mann-Whitney 
test). The delivery of a leaflet or manual and injection training into a ’phantom’ had no 
influence on the scores. Interventions were crucial for self-injection (n=3) and led to a 
reduction of anxiety (n=2) and enhancement of compliance. 
 
Discussion 
 
The rising prevalence of s.c. injection therapies with their potential for problems 
during self-administration and patient concerns provides an opportunity for 
community pharmacists to strengthen their role in the health-care system. We 
developed a feasible SOP with positive outcomes, although it lacked a strong impact 
due to the patients’ already high baseline skills.  
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Regarding the score design, Cronbach’s alpha reliability coefficients between 0.58 
and 0.80 (except an α = 0.03 due to a ceiling effect) are acceptable. Removing the 
least reliable items from the scales did not increase scale reliabilities, indicating that 
the reliabilities reflect the scales as a whole and not an inconsistent item quality. The 
number of questions per domain varied (2−27 questions). This reflects that some 
domains were more complex in nature, and balancing the number of questions per 
domain would have led to a loss of information regarding these domains, as well as 
to lower reliability scores.  
Patients of the ClinS arm were more experienced in self-injecting than patients of the 
DailyS arm. As this study, as well as our previous data [35] show that patients with 
experience have less discomfort and the injections require less effort, there might be 
some bias concerning the self-assessment of the application quality. The lower 
prescription quality in the DailyS arm (lack of specification of number of daily 
injections) might be explained by the trend to more handwritten than printed 
prescriptions from more often general practitioners than hospitals. The high 
prevalence of adverse drug reactions is eye-catching. Hematoma and mild injection 
site irritation/burning account for the majority. They are typical adverse drug reactions 
of s.c. injections and might be reduced, at least to some extent, by a slow injection 
[32-34]. The use of alcohol swabs did not seem to have an influence on burning. 
Patients in the DailyS-C reported less adverse drug reactions than patients in the 
other study arms. This might be due to poorer reporting quality by the master 
students. Nevertheless, the students were skilled enough to monitor and record an 
s.c. self-injection after receiving instructions in the s.c. injection technique, including 
clinical training and the analysis of the three videos showing s.c. injections with 
purposeful errors. They showed a steep learning curve, which makes this tool a 
suitable education instrument.  
We saw no relevant correlations − neither between the domains nor between ‘Reality’ 
and ’Self-assessment’. Therefore, an objective assessment of patient skills is crucial 
and makes the time- and cost-consuming DOT worthwhile. Overall, patient baseline 
skills were high, with the lowest score being 0.86 on a range of −2.00 to +2.00, 
making further improvement difficult. Nevertheless, through our interventions, we 
could increase patients’ application quality and knowledge. Although there were no 
significant differences between the scores of the intervention groups in the clinical 
and daily life settings, the results of the two settings are not comparable, as in the 
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DailyS patients receiving interventions did not achieve better results in application 
quality and knowledge. A proper injection technique contributes to a safe and positive 
outcome. Our interventions had a positive influence on some of the clinically relevant 
administration steps, especially on hygiene and avoidance of needle stick injuries. 
Nevertheless, the contributions of the interventions resulted in no specific pattern, 
which might be explained by the relatively small study population.  
A notable, though not intended result regards the control group's assessment of the 
assistance quality. Overall, the control group felt that they received a very good level 
of care, probably because researchers have contacted them several times 
(telephone interviews, home visit), inquired about their well-being, and generally 
showed an interest in them. This shows two things: First, that patient's assessment of 
assistance quality does not necessarily rely on the quality of pharmaceutical care 
they receive, and second that this assessment can be substantially improved by 
comparatively simple means, such as asking them how they are doing.  
As the interventions of the SOP were not standardized, but patient-tailored, we did 
not focus on the time needed. The primary investigator estimated an average of 30 
min was required for both recruitment and interventions, which is in line with the 
literature (10−45 min) [83, 105, 120]. No additional care was desired and patients 
had no need of the interventions if they rated them as unhelpful (e.g. previous s.c. 
injection therapies, medical professional, good patient care in the past). This 
illustrates that we provided an SOP for first instruction by a community pharmacist 
and subsequent pharmaceutical care during self-injection which was feasible in daily 
life, that the quality of our interventions was good and adequate, and that a single 2-
hour course was sufficient. Patients in the ClinS received more oral instructions and 
injection training into a ‘phantom’. This might explain why patients in the DailyS 
assessed the leaflet as being more helpful. Oral instructions were the pivotal 
intervention of the SOP to improve the application quality. Compared to our former 
study investigating a heterogeneous outpatient population receiving standard care 
[35], patients of the two intervention groups ClinS-I and DailyS-I received more 
leaflets and manuals, injection training into a ‘phantom’, and (first) injection 
administered by or in the presence of a pharmacist. Commercial videos and patient-
tailored websites were used rarely, confirming the observations of the former study 
[35]. High-quality videos and websites should be better promoted and might be 
helpful in resolving insecurities at home after the instructions.  
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We detected a higher objective (37.4%) than subjective (12.9%) non-compliance 
rate. Similar studies reported non-compliance rates of 4.5−28.3% [35, 83, 103-105, 
121]. Assuming that our patients were honest, they might not have disposed all 
syringes in their sharps collector, they might have interpreted a 10-day course as a 
10-day postoperative and not 10-day ambulatory treatment, they might have 
administered 40 rather than 42 syringes in a 6-week course for practical reasons (= 4 
packages), or the prescription of one package (= 10 syringes) did not necessarily 
mean that all of them had to be injected. It illustrates that the syringe count was not 
very reliable, though the only way to objectively determine non-compliance. The 
overall compliance rate was high with an overall mean of 95.8%. Patients seem to 
have concerns with pre-filled syringes [35], but are aware of their need. In further 
research, we propose investigating the relation between concerns and needs of 
those injecting LMWH (pre-filled syringes) and those taking new oral direct anti-factor 
Xa or anti-thrombin inhibitors, as with oral medication, much lower compliance rates 
of about 50% are reported [59, 71]. Nevertheless, reminder systems used as a 
compliance aid, such as a daily text message (SMS) at the individual injection time, 
could be appreciated [77]. 
 
The strength of our study is the parallel implementation in community pharmacies, 
allowing: (1) investigation as to whether the interventions are feasible in daily life and, 
(2) direct comparison of the results under controlled study conditions and daily life 
conditions. Nevertheless, one has to be aware that experimental conditions were 
more strictly controlled in the ClinS arm (RCT; recruitment and data collection by one 
person (primary investigator); few places of recruitment (four hospital wards); one 
LMWH brand) than in the DailyS arm (controlled trial; recruitment and data collection 
by several persons (community pharmacists, master students, primary investigator); 
several places of recruitment (community pharmacies); all brands of LMWH). The 
main limitation of the study is the low overall consent rate of 31.8%. In the ClinS, the 
main reasons for not meeting inclusion criteria were injections administered by 
another person, change of hospital ward, discharge when bridging was completed 
(oral anticoagulants in therapeutic range), no outpatient LMWH treatment, and 
comprehension difficulties due to language. Additional challenges within the 
recruitment were the time management (patients were often already discharged, 
examinations were not yet done or diagnosis not clear, i.e. uncertainty whether the 
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patient was receiving LMWH treatment), when the informed hospital staff had days 
off, when patients were not in their room, or when they had their rehabilitation. One 
third of the community pharmacies could not recruit any patients; few LMWH 
prescriptions, the lack of course attendance by all pharmacists working there, and a 
lack of motivation might be some reasons. Also, some selection bias, observer 
expectation bias, and patient underreporting bias (negative things are not told) 
cannot totally be excluded. Rivaroxaban (Xarelto®), a new orally active antithrombotic 
drug, was licenced in Switzerland for thromboprophylaxis only in patients undergoing 
knee or hip arthroplasty in January 2009 [7, 122] and did not seem to account for a 
bias.  
 
Overall, we confirmed our hypothesis that intensive pharmaceutical care resulted in 
more safety (objectively assessed with application quality/DOT), but we had to reject 
our assumptions of improved compliance (objectively assessed with syringe count), 
more satisfaction (subjectively assessed with assistance quality), and fewer 
complications (subjectively assessed with patients’ self-reports on adverse drug 
reactions). The results of our study allow important recommendations for daily 
practice, which are: (1) offering each person with a prescription for an outpatient 
LMWH treatment a leaflet, manual, kit, sharps collector, and oral instructions in s.c. 
injection technique; (2) the first self-injection should occur in the presence of a 
medical professional to ensure proper injection technique − if not done in the 
hospital, we encourage the pharmacists to be present (at patient’s individual injection 
time) [77, 118, 123]; (3) injection training into a ‘phantom’ and further injections in the 
presence of or administered by a pharmacist are very supportive tools and should be 
applied if the patient requires lots of effort or has discomfort; and (4) potential needle 
phobia [124] and handling difficulties should be kept in mind. 
 
Conclusion 
 
Our SOP was of good quality, adequate, appreciated, feasible in the daily life of 
community pharmacies, and resulted in improved application quality and knowledge, 
despite high baseline patient skills. The home visits with the direct observation 
technique were valuable in determining patient skills. Health-care professionals 
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should invest more time in injection training into a ‘phantom’ and delivering oral 
instructions, which were the pivotal interventions in improving patients’ application 
quality. Each patient should be offered written information, alcohol swabs, a sharps 
collector, oral instructions, and first self-injection in the presence of a medical 
professional. Patients are capable of managing s.c. injection therapies in a 
satisfactory way and with high compliance if adequate assistance is provided. 
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Tables, figures, and Appendix 
 
Table 1 Generation of 7 domains  
Self-assessment (subjective by patients) 
 Application quality (6 questions; α = 0.73) 
 Assistance quality (2 questions; α = 0.80) 
 Compliance (4 questions; α = 0.58) 
Reality (objective by investigators) 
 Application quality (DOT) (27 questions; α = 0.58) 
 Assistance qualitya (SOP) 
 Complianceb 
 Knowledge (10 questions; α = 0.03)c 
a No score: interventions were done only if required. 
b No score: assessed using syringe count. 
c Ceiling effect: nearly all patients were very knowledgeable about the treatment itself 
and inconsistently ignorant about questions of recapping, drug interactions with OTC 
medication, and adverse drug reactions. Scale consistency is low because while 
patients are consistenty knowledgeable, they do not exhibit any consistent pattern 
regarding their (very limited) areas of ignorance. 
 
Outpatient low-molecular-weight heparin therapy 
 94
Table 2 Characteristics of study sample (ntotal=139) 
Patient characteristics ClinS-I 
(n=33) 
n (%)a 
ClinS-C 
(n=32) 
n (%) 
DailyS-I 
(n=40) 
n (%) 
DailyS-C 
(n=34) 
n (%) 
Total 
(ntotal=139) 
n (%) 
Missing 
data  
n (%) 
Age (years) (range 18−84) 
Male 
Education  
 Mandatory school 
 Skilled worker 
 Technical college + university 
Impairment in daily living due to arm, shoulder, or hand 
Impaired vision (using glasses or contact lenses) 
56 (34−60) 
17 (51.5) 
 
4 (12.1) 
17 (51.5) 
12 (36.4) 
3 (9.1) 
3 (9.1) 
56 (42−66) 
13 (40.6) 
 
1 (3.1) 
19 (59.4) 
12 (37.5) 
8 (25.0) 
3 (9.4) 
51 (36−65) 
23 (57.5) 
 
2 (5.0) 
24 (60.0) 
14 (35.0) 
10 (25.0) 
6 (15.0) 
54 (43−67)
16 (47.1) 
 
2 (5.9) 
23 (67.6) 
5 (14.7) 
5 (14.7) 
5 (14.7) 
54 (40−65) 
69 (49.6) 
 
9 (6.5) 
83 (59.7) 
43 (30.9) 
26 (18.7) 
17 (12.2) 
0 (0.0) 
0 (0.0) 
4 (2.9) 
 
 
 
2 (1.4) 
6 (4.3) 
Medication characteristics       
Medication 
 Fragmin (dalteparin) 
 Clexane (enoxaparin) 
 Fraxiparine (nadroparin) 
 Fraxiforte (nadroparin) 
 Sandoparin (certoparin) 
 Arixtra (fondaparinux) 
Application once daily 
 Not specified on prescription 
Reason for LMWH treatment (multiple answers possible)  
 
33 (100.0) 
 
 
 
 
 
33 (100.0) 
0 (0.0) 
 
 
32 (100.0) 
 
 
 
 
 
30 (93.8) 
2 (6.2) 
 
 
22 (55.0) 
11 (27.5) 
2 (5.0) 
1 (2.5) 
2 (2.5) 
2 (5.0) 
33 (82.5) 
7 (17.5) 
 
 
14 (41.2) 
5 (14.7) 
12 
2 (5.9) 
1 (2.9) 
0 (0.0) 
27 (79.4) 
4 (11.8) 
 
 
101 (72.7) 
16 (11.5) 
14 (10.1) 
3 (2.2) 
3 (2.2) 
2 (1.4) 
123 (88.5) 
13 (9.4) 
 
0 (0.0) 
 
 
 
 
 
 
2 (1.4) 
 
2 (1.4) 
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 Injury/orthopedic surgery 
 Thrombosis, embolism 
 Perioperative management/bridging 
 Atrial fibrillation, myocardial infarction 
 Other 
31 (93.9) 
2 (6.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
32 (100.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
31 (77.5) 
3 (7.5) 
4 
0 (0.0) 
3 (7.5) 
20 (58.8) 
3 (8.8) 
2 (5.9) 
3 (8.8) 
4 (11.8) 
114 (82.0) 
8 (5.8) 
6 (4.3) 
3 (2.2) 
7 (5.0) 
 
Parameters on patients’ self-reports       
Previous outpatient s.c. injection therapies 
History of first self-injection in the presence of a medical 
professional 
Injection site (multiple answers possible) 
 Thigh 
 Abdomen 
Adverse drug reactions (multiple answers possible) 
 Hematoma at injection site 
 Mild injection site irritation/burning 
 Hematoma in general 
 Site pain 
 Induration  
 Exanthema 
 Bleeding tendency; n=1 met criteria for reporting an  
adverse event to regulatory authority (melena) 
 Epistaxis 
 Other  
19 (57.6) 
20 (60.6) 
 
 
27 (81.8) 
13 (39.4) 
33 (100.0) 
31 (93.9) 
16 (48.5) 
2 (6.1) 
3 (9.1) 
5 (15.2) 
1 (3.0) 
1 (3.0) 
 
0 (0.0) 
2 (6.1) 
23 (71.9) 
18 (56.3) 
 
 
24 (75.0) 
15 (46.9) 
29 (90.6) 
26 (81.3) 
17 (53.1) 
2 (6.3) 
0 (0.0) 
0 (0.0) 
2 (6.3) 
0 (0.0) 
 
1 (3.1) 
2 (6.3) 
19 (47.5) 
23 (57.5) 
 
 
26 (65.0) 
18 (45.0) 
37 (92.5) 
35 (87.5) 
22 (55.0) 
5 (12.5) 
4 (10.0) 
3 (7.5) 
0 (0.0) 
1 (2.5) 
 
1 (2.5) 
9 (22.5) 
15 (44.1) 
20 (58.8) 
 
 
20 (58.8) 
16 (47.1) 
17 (50.0) * 
15 (44.1) 
5 (14.7) 
3 (8.8) 
3 (8.8) 
0 (0.0) 
0 (0.0) 
1 (2.9) 
 
0 (0.0) 
0 (0.0) 
76 (54.7) 
81 (58.3) 
 
 
97 (69.8) 
62 (44.6) 
116 (83.5) 
107 (77.0) 
60 (43.2) 
12 (8.6) 
10 (7.2) 
8 (5.8) 
3 (2.2) 
3 (2.2) 
 
2 (1.4) 
13 (9.4) 
2 (1.4) 
3 (2.2) 
 
2 (1.4) 
 
 
2 (1.4) 
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Unscheduled visit with physician/hospital 
 Exanthema; n=2 met criteria for reporting an adverse event  
to regulatory authority 
Skipping injections 
 1 time 
 >3 times 
Reason for skipping injections (multiple answers possible) 
 Forgotten 
 Not being at home 
 Early discontinuation 
 Needle phobia 
 No acceptance, no need of LMWH 
 Other 
6 (18.2) 
1/6 (16.7) 
 
4 (12.1) 
2/4 (50.0) 
0/4 (0.0) 
 
2/4 (50.0) 
1/4 (25.0) 
1/4 (25.0) 
0/4 (0.0) 
0/4 (0.0) 
2/4 (50.0) 
3 (9.4) 
2/3 (66.7) 
 
6 (18.8) 
4/6 (66.7) 
1/6 (16.7) 
 
5/6 (83.3) 
2/6 (33.3) 
0/6 (0.0) 
0/6 (0.0) 
0/6 (0.0) 
0/6 (0.0) 
5 (12.5) 
0/5 (0.0) 
 
7 (17.5) 
6/7 (85.7) 
1/7 (14.3) 
 
5/7 (71.4) 
1/7 (14.3) 
1/7 (14.3) 
1/7 (14.3) 
1/7 (14.3) 
1/7 (14.3) 
0 (0.0) 
0/0 (0.0) 
 
1 (2.9) 
1/1 (100.0)
0/1 (0.0) 
 
0/1 (0.0) 
0/1 (0.0) 
0/1 (0.0) 
0/1 (0.0) 
0/1 (0.0) 
1/1 (100.0)
14 (10.1) 
3/14 (21.4) 
 
18 (12.9) 
13/18 (72.2)
2/18 (11.1) 
 
12/18 (66.7)
4/18 (22.2) 
2/18 (11.1) 
1/18 (5.6) 
1/18 (5.6) 
4/18 (22.2) 
1 (0.7) 
0/14 (0.0) 
 
9 (6.5) 
0/18 (0.0) 
 
0/18 (0.0) 
* p≤0.05.  
a All data is presented as the number (n) with the percentage in parenthesis, with the exception of ‘Age‘, which is presented as the 
median with the interquartile range in parenthesis. 
LMWH Low-molecular-weight heparins; s.c. Subcutaneous; ClinS-I Intervention group, clinical setting; ClinS-C Control group, 
clinical setting; DailyS-I Intervention group, daily life setting; DailyS-C Control group, daily life setting 
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Table 3 Scores of the different domains (score minimum=−2.00; score maximum=+2.00) and results from the syringe count 
 ClinS-I 
(n=33) 
ClinS-C  
(n=32) 
p value 
(Mann- 
Whitney)
DailyS-I  
(n=40) 
DailyS-C  
(n=34) 
p value 
(Mann- 
Whitney)
ClinS-I +  
DailyS-I  
(n=73) 
ClinS-C +  
DailyS-C 
(n=66) 
p value 
(Mann- 
Whitney) 
Domains Scores, mean (standard deviation) 
Application quality (DOT) 1.25 (0.27) 0.86 (0.33) p<0.01 1.20 (0.41) 1.17 (0.40) p=0.80 1.22 (0.36)     1.02 (0.39) p<0.01 
Knowledge 1.10 (0.38) 0.95 (0.41) p=0.05 1.03 (0.33) 0.94 (0.40) p=0.38 1.06 (0.35)     0.95 (0.41) p=0.03 
Application quality,  
self-assessment 
1.27 (0.47) 1.34 (0.41) p=0.56 1.20 (0.53) 1.20 (0.38) p=0.97 1.23 (0.50) 1.27 (0.40) p=0.77 
Compliance,  
self-assessment 
1.43 (0.58) 1.32 (0.78) p=0.93 1.35 (0.75) 1.59 (0.38) p=0.47 1.38 (0.68) 1.46 (0.62) p=0.68 
Assistance quality,  
self-assessment 
1.09 (0.38) 1.02 (0.44) p=0.54 1.19 (0.68)  1.52 (0.62) p<0.01 1.14 (0.56)     1.28 (0.59) p=0.05 
Compliance  
(syringe count) 
%a, mean (standard deviation) 
 94.5 (10.5) 96.2 (10.6) p=0.36 95.1 (10.0) 97.5 (4.2) p=0.72 94.8 (10.2) 96.8 (7.9) p=0.40 
a Overall range 48–100%. 
ClinS-I Intervention group, clinical setting; ClinS-C Control group, clinical setting; DailyS-I Intervention group, daily life setting; 
DailyS-C Control group, daily life setting 
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Table 4 Error rates of clinically relevant administration steps and the influence of the interventions upon them 
s.c. injection steps (chronological listing) 
 
Observations during the DOTs (n=128) 
 
n (%) Missing data  
n (%) 
Intervention (ClinS-I + DailyS-I) vs. control 
(ClinS-C + DailyS-C)   
p value (Mann-Whitney test) 
No washing or disinfection of hands right before injection 85 (66.4) 2 (1.6) p=0.01 favouring intervention 
Not waiting for the alcohol to evaporate (n=124) 58 (46.8) 2 (1.6) p=0.03 favouring intervention 
Difficulties to remove needle shield 12 (9.4) 0 (0.0) p=0.84 
Need of a new pre-filled syringe due to wrong removal of 
needle shield 
1 (0.8) 2 (1.6) p=0.29 
Removal of air bubble 11 (8.6) 1 (0.8) p=0.26 
Not pinching a skin fold 15 (11.7) 0 (0.0) p=0.84 
No puncture into cleansed skin area (n=124) 1 (0.8) 0 (0.0) p=0.14 
Not inserted the full length of the needle into the skin 13 (10.2) 0 (0.0) p=0.29 
Not waited a second before withdrawing the needle 43 (33.6) 0 (0.0) p=0.19 
Skin fold released before withdrawing the needle (n=117) 12 (10.3) 1 (0.9) p<0.01 favouring intervention 
Recapping 57 (44.5) 0 (0.0) p<0.01 favouring intervention 
Syringe not disposed immediately after withdrawing the 
needle 
45 (35.2) 0 (0.0) p=0.20 
ClinS-I Intervention group, clinical setting; ClinS-C Control group, clinical setting; DailyS-I Intervention group, daily life setting; 
DailyS-C Control group, daily life setting 
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Table 5 Patients’ assessment of the received assistance quality (SOP) 
 ClinS-I  
(n=33) 
DailyS-I  
(n=40) 
ClinS-I + DailyS-I  
(n=73) 
Missing data 
 SOP, n (%) 
Assistance quality 
 Delivery of leaflet - helpful 
 Delivery of a manual - helpful 
 Delivery of a kit (alcohol/cotton swabs,  
plasters) - helpful 
 Delivery of a sharps collector - helpful 
 Oral instructions - helpful 
 Injection training into a ‘phantom’ - helpful 
 Commercial video tape - helpful 
 (First) self-injection in the presence 
 of a pharmacist - helpful 
  (First) injection administered by a  
pharmacist - helpful 
 
17/32 (53.1)              *
20/32 (62.5) 
29/33 (87.9) 
 
22/33 (66.7) 
22/31 (71.0) 
21/28 (75.0) 
0/0 (0.0) 
0/0 (0.0) 
 
1/1 (100.0) 
 
29/36 (80.6) 
24/33 (72.7) 
38/39 (97.4) 
 
26/40 (65.0) 
23/28 (82.1) 
8/9 (88.9) 
0/0 (0.0) 
3/3 (100.0) 
 
0/0 (0.0) 
 
46/68 (67.6) 
44/65 (67.7) 
67/72 (93.1) 
 
48/73 (65.8) 
45/59 (76.3) 
29/37 (78.4) 
0/0 (0.0) 
3/3 (100.0) 
 
1/1 (100.0) 
 
0/68 (0.0) 
0/65 (0.0) 
0/72 (0.0) 
 
21/73 (28.8) 
0/59 (0.0) 
0/37 (0.0) 
0/0 (0.0) 
0/3 (0.0) 
 
0/1 (0.0) 
* p≤0.05.  
ClinS-I Intervention group, clinical setting; ClinS-C Control group, clinical setting; DailyS-I Intervention group, daily life setting; 
DailyS-C Control group, daily life setting 
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Fig. 1 Study flowchart with reasons for exclusion 
LMWH Low-molecular-weight heparins 
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Appendix 
Table 1 Questions assigned to the particular domains 
Domains: 
Self-
assessment 
(subjective 
by patients) 
Application quality 
 Confidence in the beginninga / at DOT / at the endb? 
 Degree of effort required in the beginning / at the end? 
 Difficulties with removal of needle shield in the beginning / at the end? 
 Puncture painful in the beginning / at the end / throughout therapy? 
 Injection painful in the beginning / at the end / throughout therapy? 
 Self-injection or injections administered by another person in a future s.c. 
therapy? 
Assistance quality 
 Sufficiently informed about injection site? 
 Sufficiently informed about injection technique? 
Compliance 
 Difficulties with regular application of LMWH? 
 Degree of personal responsibility concerning compliance of LMWH? 
 Skipped injections (and how many)? 
 Degree of compliance concerning prescribed injection time? 
Domains: 
Reality 
(objective by 
investigators 
Application quality (DOT) 
 Pre-filled syringe / alcohol swab / cotton swab / plaster / sharps collector 
within easy reach? 
 Washing or disinfection of hands right before injection? 
 Injection site? 
 Disinfection of the skin area (e.g. by a single wipe; rubbing; no disinfection)? 
 Waited for the alcohol to evaporate / let it dry? 
 No contact with disinfected skin area? 
 Difficulties to remove needle shield? 
 Horizontal removal of the needle shield by pulling it straight off the syringe 
using both hands? 
 Need of a new pre-filled syringe due to wrong removal of needle shield? 
 Reattachment of needle shield? 
 Removal of air bubble? 
 Drop on the needle (e.g. shaken off; wiped off; left; no drop)? 
 Pinched a skin fold (e.g. an inch; less than an inch; no skin fold)? 
 Puncture into cleansed skin area? 
 Full length of the needle inserted into the skin?  
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 Waited a second before withdrawing the needle? 
 Thumb grip pressed when withdrawing the needle? 
 Needle withdrawn at the same angle that it was inserted? 
 Skin fold released after withdrawing the needle? 
 Skin area swabbed after injection (e.g. swabbing gently; rubbing; no 
swabbing)? 
 Investigator’s assessment of patient’s confidence 
 Syringe disposed immediately after withdrawing the needle? 
 Recapping? 
Assistance qualityc 
Complianced 
Knowledge 
 Consistency with prescribed therapy duration? 
 Consistency with prescribed daily injections? 
 Consistency with prescribed injection time? 
 Injection site? 
 Recapping? 
 Reason for LMWH treatment? 
 Potential interactions with over the counter medication? 
 Potential adverse drug reactions? 
 Action taken if mild injection site irritation, burning or hematoma at injection 
site occurred? 
 Action taken if sudden malaise occurred? 
a Asked for at telephone interview. 
b Asked for at final interview. 
c No score: interventions were carried out only if required. 
d No score: syringe count used. 
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4 General discussion and conclusions 
In this thesis, we evaluated the characteristics and prevalence of drug use problems 
and handling difficulties with pre-filled LMWH syringes and the impact of 
pharmaceutical care on outpatient s.c. injection therapies. 
 
Project A is based upon the reports from patients and nurses experiencing 
considerable difficulties when removing the needle shields of some LMWH pre-filled 
syringes. The triangulation of methods ─ comprising self-assessment by a study 
population, simultaneous observer’s assessment, and the determination by 
mechanical pull-off tests ─ allowed evaluations of the degree of force required to 
remove the cap.  
The objective mechanical pull-off tests confirmed the results from the subjective self- 
and observer’s assessments. Despite international conferences on pre-filled 
syringes, manufacturers seemed to be unaware of this drug use problem, as we 
detected significant differences between different brands and even between different 
lots of the same brand, and as we were unable to find studies or an ISO-norm.  
Forces needed to remove the needle shields (14─30 N) were in line with the forces 
required to handle with other medication, packaging, or devices (4─80 N) [38-40, 44]. 
Nevertheless, as maximal pinch strength decrease with age [38, 42], the cap-pull-off 
forces for LMWH devices might be too high for some patients, leading to 
unintentional, complete non-compliance. Even within our young study population 
(median age of 29 years), 4 out of 68 persons were not able to remove all needle 
shields.  
The take-home message for us was that handling difficulties and drug use problems 
with medication, packaging, or devices might occur where neither the pharmaceutical 
industry, nor manufacturers, researchers, or community pharmacists would expect 
them to happen. It outlines the importance of the pharmacists’ role in recognizing and 
preventing handling difficulties by offering an extensive first instruction, by monitoring 
patients’ first self-administration under daily life conditions, and by a periodic 
outcome evaluation. 
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The main objectives of project B were to compile a complete list of drug use 
problems and handling difficulties with pre-filled syringes under daily life conditions 
and to objectively assess the compliance of outpatients on an s.c. injection treatment. 
The results should highlight potential areas for improvements in patient care through 
specific interventions to be used for the main study (project C).  
Drug use problems were either associated with the handling of the injection-device or 
with the injection technique. Among our study participants, 85.0% experienced at 
least one relevant problem, with recapping being the most frequent difficulty 
encountered (73.7%). Only indirect measurement methods were used to assess 
patient compliance. We skipped the syringe count due to poor reliability: as a result 
of the daily life conditions, prescriptions were often incomplete, dates of the last 
injection were frequently missing, and not all used syringes were discarded into the 
sharps collectors. We therefore determined the amounts of residual drug volumes in 
the used syringes, which was ─ to our knowledge ─ a new approach. However, the 
potential evaporation of the residual liquid limited the validity of this measurement 
tool. The overall mean residual drug volumes were negligible. If residual drug was 
present, though, it tended to be of pharmacological relevance. As far as we know, no 
other study has analyzed the used syringes to this extent (percentage of recapping 
and properly activated post-injection needle guards, determination of residual drug 
volumes, syringe count). Our results clearly indicate the need for further investigation 
of medications with relevant injection volumes (≥0.5 ml). 
Apart from the residual drug, no clear factors were associated with the injection site. 
Thus, our study concluded that from the application point of view, the two injection 
sites abdomen and thigh can equally be recommended. Patients at highest risk for 
drug use problems, handling difficulties, and leaving residual drug volumes are those 
who inject high volumes into the thigh, whose treatment requires a low application 
frequency, and who are at high risk of being impaired in fine motor skills. 
Methotrexate patients, fulfilling most of these characteristics and administering a 
cytotoxic agent, therefore demand special care. Extensive patient education and 
instruction in the s.c. injection technique as well as periodic monitoring of patient self-
administrations are particularly important within this population. 
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Based upon our experiences from projects A and B, in project C we aimed to 
develop an SOP for the first instruction in the s.c. injection technique given by a 
community pharmacist and the subsequent pharmaceutical care provided during 
outpatient therapy. To assess its effectiveness, we compared the intensive 
pharmaceutical care with standard care in both a clinical setting (hospital wards 
under study conditions) and in a daily life setting (community pharmacies following 
their daily routine).  
With respect to our initial hypotheses, our study was not able to show an impact of 
pharmaceutical care on compliance, satisfaction, or complications. High baseline 
skills and good compliance behaviour reduced the potential for change in patients 
receiving interventions. Nevertheless, intensified pharmaceutical care resulted in 
improved safety (better s.c. injection technique) and knowledge. And, especially, we 
could prove the feasibility of the interventions in daily pharmacy practice. Thus, our 
results confirmed the conclusions of an extensive review: that overall the 
effectiveness of PC remains unclear [55]. High baseline compliance behaviour 
seems to be a common phenomenon under study conditions: a review of the 
effectiveness of community pharmacist’s interventions showed that in 38% of the 
studies, a change in compliance could not be observed [67]. The same might be true 
for patients’ baseline skills in general. Inadequate sample sizes might be the limiting 
factor [67].  
 
The dynamic, patient-centered PC process can be illustrated nicely by using the 
example of our main study (Fig. 7). Suboptimal outcomes might have arisen from 
inappropriate patient behaviour (non-compliance, handling difficulties), inappropriate 
delivery (by the community pharmacy), or inappropriate prescribing. DRP might have 
comprised improper drug selection (by the GP), failure to receive the drug as 
intended, adverse drug reactions, or drug interactions.  
The pharmaceutical industry and manufacturers could support the community 
pharmacists in performing PC and the patients in achieving optimal outcomes by 
developing improved packaging: the secondary packaging could act as sharps 
collector at the same time and be equipped with alcohol swabs and an Universal 
Serial Bus (USB) stick containing written instructions in the s.c. injection technique 
and a video. 
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Fig. 7 The pharmaceutical care process illustrated on the example of the main study 
(project C) 
DOT Direct observation technique; DRP Drug-related problems; DVT Deep vein 
thrombosis; PC Pharmaceutical care; PE Pulmonary embolism 
 
 
Non-compliance was mostly unintentional comprising ‘drug holidays’ or wrong 
therapy durations, and was attributed to patient-related factors. Our strategies to 
improve compliance behaviour included multifaceted interventions, such as written 
and oral patient information, patient education, motivational interview, telephone 
follow-up, self-monitoring (use of diaries), close support (home visit), and 
involvement of relatives if needed. Although we used only indirect measurement 
methods to assess patient compliance behaviour (patient self-report, diaries, syringe 
count, residual drug volumes), we applied a multi-method approach combining self-
reports and objective measures as recommended [62]. Though being the only way to 
objectively determine non-compliance (despite the determination of the residual drug 
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volumes), the syringe count also turned out to be not very reliable in this study, 
confirming the observations from project B. 
 
In our main study (project C), the overall compliance rate was high with an overall 
mean of 95.8%. In the literature, non-compliance rates of 4.5−28.3% are found with 
outpatient LMWH treatments [35, 83, 103-105, 121]. Patients seem to have concerns 
with pre-filled syringes [35, 124], but are aware of their need. However, as poor 
compliance has been proved to be a worldwide phenomenon of striking magnitude 
with a prevalence of about 50%, it might not only be disease- and time-dependent 
[57-62], but also device-dependent. Patients needing to inject themselves with a 
medication might rate the necessity of the treatment higher than when swallowing 
‘just an additional’ pill. With the rising number of new oral antithrombotic drugs on 
one hand and pre-filled injection systems on the other hand, we propose to 
investigate the following research questions in the future:  
 comparison of concerns and needs [71, 72] between patients self-
administering s.c. injections and patients taking oral medication on short-term 
treatments (e.g., LMWH vs. new oral direct factor Xa or thrombin inhibitors) 
 comparison of concerns and needs between patients self-administering s.c. 
injections and patients taking oral medication on long-term treatments (e.g., 
methotrexate patients) 
 
The transfer from the clinical setting in hospital wards under study conditions to the 
daily life setting in community pharmacies following their daily routine worked very 
well. Although under study conditions the results were slightly better, it was very 
encouraging that the SOP was feasible and appreciated in the daily life of community 
pharmacies. Our strategy of a single 2-hour training course, including theoretical and 
practical sessions, close support, and the provision of interventions requiring no more 
than 30 min might be reused for the implementation of other pharmaceutical services 
in the future. The method of ‘learning from mistakes’, which we applied to the 
analysis of the three videos showing s.c. injections with purposeful errors, proved to 
be a very suitable tool for educational purposes.  
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The major challenges of this thesis were: 
 
 The development and validation of  
(1) an appropriate questionnaire for data collection 
(2) domains and scores as outcome measures  
(3) an appropriate tool to monitor and assess patient’s s.c. injection 
technique in the context of a direct observation technique (DOT) during 
a home visit 
 The standardization of data collection 
 The development and performance of training courses for community 
pharmacists and Master’s students 
 The development and provision of patient-tailored interventions for outpatients 
on an s.c. injection therapy, such as written information material (leaflet, 
manual) 
 The development of new methods, such as the determination of residual drug 
volumes in used syringes or the objective determination of forces needed to 
remove the needle shields from pre-filled LMWH syringes by mechanical pull-
off tests  
 The recruitment of an adequate number of study participants  
 
In conclusion this thesis shows the following: 
 
 The pull-off forces required to remove the needle shields of LMWH pre-filled 
syringes correspond roughly to the force needed to hold a narrow-neck plastic 
flask containing 1─3 l of water by pinching the neck between a finger and 
thumb. This seemed to be an unnoticed drug use problem so far. 
 
 Drug use problems with outpatient s.c. injection therapies are very prevalent, 
diverse, and complex. They may be associated with the injection itself or with 
the handling of the injection-device. No associations with any factors studied 
were observed with non-compliance, the injection site (beside residual drug), 
and discomfort or effort required (beside prior injection use).  
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 The overall mean residual drug volume was negligible, but the total injection 
volume seemed to have an influence. If residual drug was present, however, it 
tended to be of pharmacological relevance. Patients injecting into the thigh 
showed a higher risk of leaving medication.  
 
 From a patient’s point of view, injections require some effort. Patients have 
concerns with pre-filled syringes, but are aware of their need. Further research 
should investigate whether compliance is not only disease- and time-
dependent, but also device-dependent. We assume that intentional non-
compliance might be lower with s.c. self-injections than with oral 
administration. 
 
 The provided SOP for pharmacist interventions was of good quality, adequate, 
appreciated by the patients, and feasible in the daily life of community 
pharmacies. It resulted in improved s.c. injection technique and knowledge, 
despite high baseline patient skills. The home visits with the direct observation 
technique (DOT) were valuable in determining patient skills. Patients are 
capable of managing s.c. injection therapies in a satisfactory way and with 
high compliance if adequate assistance is provided. 
 
 Overall, we confirmed our hypothesis that intensive pharmaceutical care for 
outpatients self-injecting LMWH resulted in more safety (objective assessment 
of the s.c. injection technique during the DOT), but we had to reject our 
assumptions of improved compliance, more satisfaction, and fewer 
complications. 
 
 Our recommendations for daily practice are:  
(1) offering each person with a prescription for an outpatient s.c. injection 
treatment written information (leaflet, manual), application aids (alcohol 
swabs, sharps collector), and oral instructions (being the pivotal 
intervention in improving patients’ s.c. injection technique) 
(2) the first self-injection should occur in the presence of a health-care 
professional to ensure proper injection technique (at patient’s own 
individual injection time) 
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(3) injection training into a ‘phantom’ and further injections in the presence 
of or administered by a pharmacist are very supportive tools and should 
be applied if the patient requires lots of effort or has discomfort 
(4) potential needle phobia and handling difficulties should be kept in mind 
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